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Abstract
Protein citrullination plays a role in several autoimmune diseases. Its involvement in murine 
and human type 1 diabetes has recently been recognized through the discovery of antibodies 
and T-cell reactivity against citrullinated peptides. In the current study, we demonstrate that 
systemic inhibition of peptidylarginine deiminases (PADs), the enzymes mediating 
citrullination, through BB-Cl-amidine treatment, prevents diabetes development in NOD mice. 
This prevention was associated with reduced levels of citrullination in the pancreas, decreased 
circulating autoantibody titers against citrullinated GRP78 and reduced spontaneous NETosis 
of bone marrow-derived neutrophils. Moreover, BB-Cl-amidine treatment induced a shift from 
Th1 to Th2 cytokines in the serum and an increase in the frequency of regulatory T cells in the 
blood and spleen. In the pancreas, BB-Cl-amidine treatment preserved insulin production and 
was associated with a less destructive immune infiltrate, characterized by reduced frequencies 
of effector memory CD4+ T cells and a modest reduction in the frequency of IFNγ-producing 
CD4+ and CD8+ T cells. Our results point to a role of citrullination in the pathogenesis of 
autoimmune diabetes, with PAD inhibition leading to disease prevention through modulation 
of immune pathways. These findings provide insight in the potential of PAD inhibition for 
treating autoimmune diseases like type 1 diabetes. 
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Introduction
Emerging evidence demonstrates a role for post-translational modifications (PTMs) in the 
pathogenesis of type 1 diabetes (1–10). One of these PTMs is citrullination, the conversion of 
arginine into citrulline, mediated by peptidylarginine deiminases (PADs), of which 5 isozymes 
have been described (11). The loss of a positively charged arginine in peptides enhances their 
binding affinity to type 1 diabetes predisposing HLA-DR4 molecules (12,13) and may thereby 
elicit autoreactive T-cell responses. Indeed, it has been shown that autoreactive CD4+ T cells 
of patients with type 1 diabetes recognize citrullinated GAD65 (4). Moreover, our group 
showed that citrullinated glucose regulated protein 78 (GRP78) is an autoantigen in NOD mice 
and in human type 1 diabetes (5,6,10). We also provided direct evidence for cytokine-induced 
citrullination of GRP78 in INS-1E beta-cells (5) and human islets (10), indicating that GRP78 
can be citrullinated in beta-cells in the absence of immune cells. In addition, we showed that 
inflammatory cytokines induce translocation of GRP78 from the endoplasmic reticulum to the 
beta-cell membrane and its subsequent secretion (5,14), providing the ideal environment to 
become citrullinated in the extracellular space (15). Although it remains unknown which cells 
are responsible for protein citrullination in the pancreas, PAD2 is highly expressed in NOD 
islets relative to C57Bl/6 islets (5,16). Also increased levels of PAD4 in neutrophils of type 1 
diabetes individuals have been reported (17,18). Interestingly, PAD4 is crucial for the 
formation of neutrophil extracellular traps (NETs) (19), a process associated with the 
pathogenesis of type 1 diabetes (20,21). Neutrophils are the first immune cells to infiltrate the 
islets of NOD mice (20) and have been found in the human pancreas prior to disease onset (21), 
with a substantial fraction forming NETs (21). Moreover, different studies targeting neutrophil 
activity or NETs showed a marked protection against diabetes development in NOD mice 
(20,22–24). 
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Citrullination does not occur exclusively in type 1 diabetes. In other autoimmune diseases, 
citrullinated proteins are present in inflamed target tissues and are associated with the break in 
immune tolerance (25). In rheumatoid arthritis, for example, citrullinated autoantigens are 
known to be causative (25). Several studies have reported improved disease outcome without 
any signs of in vivo toxicity (26–30) using pan-PAD inhibitors, such as Cl-amidine or BB-Cl-
amidine, in animal models for rheumatoid arthritis (26,31,32), multiple sclerosis (33), systemic 
lupus erythematosus (30,34) and ulcerative colitis (27–29). Disease improvement, through 
direct inhibition of citrullination, was shown to be linked to decreased NET formation 
(NETosis) (34–37), modulation of dendritic cell function (37) and a shift in Th1/Th2 profiles 
(31). Based on these results, PAD inhibition is gaining interest as a strategy to treat or prevent 
autoimmune diseases that are associated with abnormal PAD activity. 
The mechanism by which BB-Cl-amidine and its mother compound Cl-amidine inactivates 
PAD has been well described (38). Both compounds irreversibly inactivate PAD enzymes 
through covalent modification of a conserved cysteine in the active site of the PAD enzymes, 
thereby having an effect on all PAD enzymes. When PAD enzymes become activated they 
undergo a calcium-dependent conformational change that moves a nucleophilic cysteine 
residue into the active site and, only then, this cysteine is available for the PAD inhibitor (38). 
Compared to Cl-amidine, BB-Cl-amidine has a longer in vivo half-life (1.75 h vs. ~15 min), a 
higher cellular potency (EC50 of 8.8±0.6 µM vs >200 µM for Cl-amidine) and a comparable 
selectivity for the different PAD enzymes (34). With no reports on the potential efficacy of 
PAD inhibition in type 1 diabetes models, we here evaluated the effect of BB-Cl-amidine in 
NOD mice. We observed full protection against diabetes development, associated with a 
decrease in citrullination and in autoantibody titers against citrullinated GRP78. Effects on 
innate and adaptive immune responses were also observed, with decreased NETosis of bone 
marrow-derived neutrophils, increased serum Th2 cytokines and regulatory T cells (Treg) in 
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peripheral tissues, and a decrease in effector memory CD4+ T cells (TEM) and IFNγ-producing 
CD4+ and CD8+ T cells in the pancreas. These findings point to a role for dysregulated PAD 
activity and citrullination in autoimmune diabetes and provide initial insight into PAD 
inhibition as a potential therapeutic strategy.
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Research Design and Methods
Mice and treatment regimen
Non-obese diabetic (NOD) mice were inbred and housed under semi-barrier conditions in our 
animal facility. Eight-week-old female NOD mice were used. Treatments involved 
subcutaneous injections with BB-Cl-amidine (1µg/g body weight) or vehicle (25% DMSO in 
PBS) six times per week until 25 weeks of age for diabetes incidence, or until 13 weeks of age 
for mechanistic studies (29,31,34,39). Experiments were approved by the Institutional Animal 
Ethics Committee of KULeuven. 
Dispersion of murine islets and sorting 
Islets were isolated from 10-week-old NOD mice using collagenase (40). After overnight 
resting, the islets were dispersed into single-cell suspensions by incubation for 90sec at 37°C 
in 0.025% trypsin-EDTA (Thermo Fisher). Cells were surface stained for cell sorting by flow 
cytometry as described (40). A detailed protocol is provided in Supplementary data.
RNA isolation, cDNA synthesis and qPCR
RNA isolation and cDNA generation was performed as previously described (40). SYBR green 
qPCR was performed on a QuantStudio 3 (Thermo Fisher) per manufacturer's instructions. 
Gene expression levels of insulin 1 (Ins1), glucagon (Glc), CD45, Padi2 and Padi4 were 
normalized to the geometrical mean of 3 housekeeping genes (actin, RPL27 and HPRT) and 
analyzed by relative quantification using the 2^-ΔCt method.
Immunohistochemistry
Page 6 of 68Diabetes
7
Five-µm sections of paraffin embedded pancreata were collected at 50µm intervals. Heat-
mediated antigen retrieval was performed on deparaffinized sections using citrate buffer 
(pH6.1; 20min, Dako). To detect citrullination, endogenous peroxidase activity was blocked 
with 0.5% H2O2 in methanol for 20min. Sections were incubated with rabbit anti-citrulline 
(1:50, Abcam) for 1h and with anti-rabbit HRP Envision (Dako) for 30min. Sections were 
incubated with DAB (Dako), counterstained with haematoxylin (2min), dehydrated and 
mounted with DEPEX. For insulin detection, sections were blocked with 10% normal goat 
serum (Dako) for 20min and incubated with guinea pig anti-insulin (1:150, Dako) for 1h and 
Alexa Fluor®633-conjugated goat anti-guinea pig (1:500, Life) for 30min. Sections were 
counterstained with Hoechst (1:2000, Thermo Fisher) and mounted with Mowiol 
(Polysciences). All incubations were done at room temperature (RT). Imaging was performed 
using an Olympus BX41 or Zeiss LSM 780 confocal NLO microscope.
Diabetes incidence
Mice were tested for clinical signs of diabetes by evaluating glucose levels in the urine with 
Diastix Reagent Strips (Bayer). As soon as glucosuria was measured, further follow-up was 
done by measuring blood glucose levels. Mice were considered diabetic when glucosuria was 
present and blood glucose levels were higher than 200mg/dL for two consecutive days.
Insulitis
At least 25 islets per mouse were scored for lymphocytic infiltration in a blinded manner using 
hematoxylin-eosin stained sections. 
Insulin content
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Pancreata were homogenized in acidic ethanol (91% ethanol, 9% 1M H3PO4) at 4°C overnight 
and sonicated. Insulin content was determined in the supernatant by ELISA (Mercodia) and 
normalized to the weight of the pancreas.   
SDS-PAGE and Western blotting 
Protein samples (50µg) were separated on 4-12% Bis-Tris gels (Invitrogen) and blotted onto 
PVDF membranes (Hybond-ECL, GE Healthcare). To detect citrullination, the anti-modified 
citrulline Kit (Millipore) was used. Membranes were incubated with SuperSignal™ West 
Femto Maximum Sensitivity Substrate (Thermo Fisher) and revealed using the ImageQuant 
LAS 500 system (GE Healthcare). Blots were normalized by re-probing for GAPDH (Thermo 
Fisher).
Proteomic analysis making use of biotin-phenylglyoxal labeling 
DMSO (n=4) and BB-Cl-amidine treated (n=4) mice pancreata were pooled in buffer (50mM 
HEPES pH 7.6, 0.5% NP40 and 1mM PMSF) and homogenized using a tissue homogenizer 
(maximum speed, 3x20sec at 10min intervals). The lysed tissue samples were centrifuged 
(12,000 rpm, 30min) at 4°C. The supernatants were isolated, and the protein concentration was 
determined using the DC™ (detergent compatible) assay. Equal protein concentrations from 
DMSO and BB-Cl-amidine treated samples were labeled with biotin-phenylglyoxal (biotin-
PG) in quadruplicate as previously described (41). A detailed protocol is provided in 
Supplementary data.
TMT labeling and LC-MS/MS analysis
A total of eight peptide digests were obtained from quadruplicate biotin-PG labeling of the 
DMSO and BB-Cl-amidine treated samples. The samples were labeled using a TMT labeling 
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system and prepared for LC-MS/MS analysis on a NanoAcquity UPLC (Waters Corporation) 
coupled to an Orbitrap Fusion Lumos Tribrid (Thermo Fisher) mass spectrometer. The raw 
data were processed using Proteome Discoverer (Thermo Fisher, version 2.1.1.21) and 
searched against SwissProt murine (downloaded 07/2019) database using Mascot (Matrix 
Science, version 2.6.2). A detailed protocol is provided in Supplementary data. 
Autoantibody assays
Mouse serum autoantibody levels against citrullinated GRP78 were determined by an in-house 
developed MesoScale Discovery (MSD) ELISA.  In vitro citrullinated GRP78 (IVC GRP78) 
was generated as described (5). Multi-array 96 plates (MSD) were coated (overnight, 4°C) with 
5µg/mL IVC GRP78 in PBS (pH 7) or with 3% skimmed milk in PBS (uncoated control). 
Blocking was performed with 3% skimmed milk in PBS with 0.5% Tween 20 (2h at RT). 
Mouse serum was diluted 1:5 in blocking solution and incubated for 2h at RT. Wells were 
incubated for 2h at RT with SULFO-TAG labeled goat anti-mouse IgG. Read buffer was added 
and detection was done on an MSD reader. To exclude nonspecific signals, each sample had 
its background signal (serum binding in uncoated well) subtracted from the reading.
NETosis
Bone marrow-derived cells were harvested from the humeri, tibias and femurs and neutrophils 
were isolated using the Neutrophil Isolation Kit (Miltenyi). Neutrophils were cultured on 
coverslips, pre-coated with 0.01% Poly L-lysine (Sigma), for 3h at 37°C in 5% CO2. 
Paraformaldehyde-fixed neutrophils were stained with Hoechst (Thermo Fisher) and NETosis 
was quantified blindly using a Nikon Eclipse TI microscope. Percentage of NET releasing cells 
was calculated by normalizing to the total amount of cells. Images were taken on a Zeiss LSM 
880 confocal Airyscan microscope. 
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Cytokine measurement in serum
Serum levels of IFNγ, IL-4 and IL-10 were determined using a V-plex assay from MSD, by a 
single measurement. All concentrations were above the lower limit of detection (LLOD). 
Immune cell phenotyping
Blood was incubated 3 times with NH4Cl to lyse red blood cells. Single cell suspensions from 
spleen were obtained by mechanical disruption, while the pancreas was enzymatically digested 
for 15min at 37°C in RPMI (72400, Thermo Fisher) supplemented with 5% bovine serum, 
0.05mM beta-mercaptoethanol, 100U/mL penicillin, 100U/mL streptomycin, 1mg/mL 
collagenase VII and 0.02mg/mL DNase I. For phenotypic characterization of Treg, TEM, central 
memory (TCM) and naïve (Tnaïve) T-cell subsets, cell suspensions were stained with Zombie 
Yellow Fixable Viability dye (Biolegend) and with antibodies against CD4 (BD), CD3, CD8, 
CD44, CD62L, CD25 and Foxp3 (eBioscience). Intracellular staining was performed with 
Foxp3/Transcriptional Factor Staining Buffer Set (eBioscience). To evaluate the effect of BB-
Cl-amidine treatment on cytokine production, 5 x 105 cells from the spleen and pancreas were 
stimulated in vitro with 0.025µg/mL phorbol-12-myristate-13-acetate (PMA) (Sigma) and 
0.25µg/mL ionomycin (Sigma) in the presence of GolgiStop (1:500, BD) for 4h at 37°C in 5% 
CO2. Next, cells were incubated with antibodies against CD4 and CD8, treated with 
Cytofix/Cytoperm (BD), and stained with anti-IFNγ antibody (eBioscience). Samples were 
acquired on a BD FACS Canto II and analyzed with FlowJo software (TreeStar). The 
percentage of cytokine-producing cells was determined and the expression level of the 
cytokine was assessed using geometric mean fluorescence intensity (MFI). For each 
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experiment, the geometric MFI of each sample was normalized to the average geometric MFI 
of the DMSO group (MFI fold change). 
Statistics
Data were analyzed using GraphPad Prism 8 or Scaffold software. Diabetes incidence was 
evaluated by Kaplan-Meier survival analysis with Mantel-Cox log-rank test. Data were 
expressed as mean ± SEM and, after exclusion of outliers, data were analyzed by one-way 
ANOVA, unpaired t-test with Welch’s correction, or Mann-Whitney U test, as indicated. 
P<0.05 was considered statistically significant.
Data and Resource Availability
All datasets generated during the current study are available from the corresponding author 
upon request.
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Results
 Pancreatic islets express Padi2 both in endocrine and in infiltrating immune cells
Although we have previously shown that islets of 3- and 10-week-old NOD mice have elevated 
PAD activity levels and enhanced Padi2 mRNA expression compared to C57Bl/6 islets (5), it 
remains to be elucidated which cell population within the islets is responsible for this high PAD 
activity. To investigate this, we performed flow cytometry sorting on 10-week-old NOD islet 
cells making use of an antibody panel consisting of CD71, CD24, CD49f and CD45 to enable 
isolation of highly purified alpha- and beta-cells (40), as well as immune cells. The purity of 
immune cell fraction was confirmed by marginal expression of insulin 1 (ins1) and glucagon 
(glc). Purity of alpha- and beta-cell fractions was confirmed by complete absence of leukocyte 
marker CD45 in both fractions, and marginal expression levels of glc (in beta-cells) and ins1 
(in alpha-cells) (Fig. 1A-C). In immune, as well as in alpha- and beta-cells, Padi2 was clearly 
expressed (Fig.1D), with a trend to higher levels in immune and beta-cells, as compared to 
alpha-cells. Of note, Padi4 mRNA levels were below the detection limit (data not shown). In 
line with this, immunohistochemical analysis of citrullination in pancreas sections of NOD 
mice demonstrated intense staining in infiltrated immune cells, while endocrine islet cells 
stained weakly positive.  Parallel staining in age-matched C57Bl/6, also showed citrullination 
in the endocrine islet cells (Fig. 1E and Suppl. Fig. 1). These results indicate that citrullination 
occurs in immune cells infiltrated in the islets and, also in endocrine alpha- and beta-cells even 
in non-pathological conditions.
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BB-Cl-amidine treatment prevents diabetes development in NOD mice and preserves 
insulin production
To examine the role of citrullination on diabetes development, NOD mice were treated with 
BB-Cl-amidine. Treatment was started at 8 weeks of age, a time point at which insulitis is 
already ongoing in NOD mice. BB-Cl-amidine treatment fully prevented diabetes 
development, with all mice free of diabetes until 25 weeks of age, against 44% diabetes-free 
in DMSO treated mice (P<0.001; Fig. 2A). Therapy was well tolerated as confirmed by normal 
weight curves (Suppl. Fig. 2). Evaluation of pancreatic insulin content at 13 weeks of age, 
before the onset of diabetes, showed a 4-fold increase of insulin in the pancreas of BB-Cl-
amidine treated mice compared to the control (P<0.01; Fig. 2B and C), pointing to preserved 
insulin production in BB-Cl-amidine treated mice. 
BB-Cl-amidine treatment reduces citrullination in the pancreas and autoantibody 
formation against citrullinated GRP78
To evaluate the direct effect of BB-Cl-amidine on inhibition of citrullination, we performed 
immunohistochemical staining of citrullinated protein residues on pancreatic sections, showing 
a reduced staining intensity in BB-Cl-amidine treated compared to DMSO treated mice (Fig. 
3A and Suppl. Fig. 3). Quantification of the overall level of citrullinated proteins in the 
pancreas of BB-Cl-amidine and vehicle-treated NOD mice by Western blotting demonstrated 
that PAD inhibition reduced the total level of protein citrullination by about 50% (P<0.01; Fig. 
3B and C). This finding was further confirmed and extended by more quantitative LC-MS/MS 
analysis. A total of 1,003 citrullinated proteins were identified in pancreata from BB-Cl-
amidine and vehicle treated mice, of which 765 were significantly decreased in abundance by 
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the treatment regimen (Fig. 3D and Suppl. Table 1 and 2). Interestingly, citrullinated GRP78, 
reported by our group as an autoantigen in murine and human type 1 diabetes (5,10), was the 
most significantly reduced citrullinated protein, with a decrease of 2.66-fold (P<0.0001). We 
have previously reported the generation of autoantibodies against citrullinated GRP78 in NOD 
mice (5). In line with this, we observed here that BB-Cl-amidine treatment decreased 
autoantibody titers against citrullinated GRP78, both at 13 (P<0.05; Fig. 3E) and 25 weeks of 
age (P<0.05; Fig. 3F). 
BB-Cl-amidine treatment decreases spontaneous NET formation in bone marrow-
derived neutrophils
Neutrophils have been suggested to play an important role in the pathogenesis of autoimmune 
diabetes, as they are the first immune cells to infiltrate the islets of NOD mice (20). Also in 
type 1 diabetes patients, neutrophil infiltration is observed in the pancreas, even prior to disease 
onset, with some degree of NETosis (21). Since citrullination is a prerequisite for the initiation 
of NETosis, we questioned here if BB-Cl-amidine treatment could have an impact on the 
propensity of neutrophils to form NETs. To this end, spontaneous NETosis was assessed in 
bone marrow-derived neutrophils isolated from BB-Cl-amidine or vehicle-treated mice. 
NETosis was significantly reduced in neutrophils from mice treated with BB-Cl-amidine 
(P<0.05; Fig. 4). This finding shows that systemic administration of BB-Cl-amidine has an 
effect on the capacity of neutrophils to form NETs. 
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BB-Cl-amidine alters the phenotype and cytokine production of immune infiltrate in the 
islets 
The finding of preserved insulin production by BB-Cl-amidine tempted us to investigate the 
degree and phenotype of immune infiltration. To this end, immunohistochemical evaluation of 
islet immune infiltration at 13 weeks of age showed only a moderate overall decrease of 
insulitis in the BB-Cl-amidine group (Fig. 5A), suggesting a less destructive form of insulitis. 
To evaluate this further, we measured in vitro cytokine production of the immune cells isolated 
from the pancreas. Although the overall frequency of IFNγ-producing T cells was low in both 
groups, mice treated with BB-Cl-amidine presented a significantly lower percentage of IFN-
producing CD4+ and CD8+ T cells (P<0.01 and P<0.05 respectively; Fig. 5B and C). Evaluating 
the phenotype of immune cells in the pancreas (representative gating strategy in Suppl. Fig. 
4A), revealed a significant decrease in the percentage of CD4+ TEM cells (P<0.05; Fig. 5E) in 
BB-Cl-amidine treated mice, whereas no changes were observed in the frequency of Treg (Fig. 
5D). No differences were observed in CD4+ and CD8+ Tnaïve and TCM subsets (Suppl. Fig. 5). 
Collectively, these data indicate that, although only a minor change in the overall level of 
insulitis, BB-Cl-amidine alters the phenotype of infiltrating immune cells, as demonstrated by 
the decrease in Th1 cytokine production and reduction of TEM cells locally in the pancreas.  
BB-Cl-amidine treatment is associated with a Th1 to Th2 serum cytokine shift, and of 
TEM to Treg in the periphery
Next, we sought to investigate the effect of BB-Cl-amidine treatment on Th1 and Th2 profiles 
and immune cell phenotype in the periphery, as BB-Cl-amidine has been shown to act through 
this pathway in other disease models (31). First, we measured serum levels of Th1 and Th2 
cytokines in BB-Cl-amidine or vehicle-treated NOD mice. Whereas no significant changes 
were measured in circulating IFNγ titers (Fig. 6A), IL-4 and IL-10 titers were significantly 
increased in the BB-Cl-amidine treated group (P<0.01 for both; Fig. 6B and C). This resulted 
in an overall reduction in the IFN/IL-10 ratio (P<0.05; Fig. 6D) (42). In the spleen of BB-Cl-
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amidine treated mice, there was a decrease in IFN production indicated by the reduced 
frequency of IFN-producing CD4+ T cells (P<0.01; Fig. 6E), as well as the lower expression 
of IFN in IFN-producing CD4+ and CD8+ T-cell populations (P<0.0001 for both; Fig. 6F and 
H). To specifically investigate the effect on the cellular phenotype of immune cell subsets, we 
used flow cytometry to study T-cell subsets in the blood and spleen (representative gating 
strategy in Suppl. Fig. 4B and C). This revealed that BB-Cl-amidine induced a significant 
increase in the percentage of Treg in blood (P<0.05; Fig. 7A) and spleen (P<0.01; Fig. 7D). 
Regarding TEM (CD4+ and CD8+) in the periphery, there was a significant decrease in the 
percentage of CD4+ TEM cells in the blood and of splenic CD8+ TEM cells (P<0.05 and P<0.001, 
respectively; Fig. 7B and F). No changes were observed in CD4+ and CD8+ TCM populations 
in the blood and spleen, whereas CD4+ and CD8+ Tnaïve in blood (both P<0.05; Suppl. Fig. 6A 
and C) and CD8+ Tnaïve in spleen (P<0.01; Suppl. Fig. 6G) were increased in BB-Cl-amidine 
treated mice. These findings suggest that in the periphery, BB-Cl-amidine induces a shift 
towards Th2 cytokine production, a decrease in TEM cells and an induction of Treg cells. 
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Discussion
This study describes the effect of the pan-PAD inhibitor BB-Cl-amidine, showing a complete 
prevention of diabetes development in NOD mice. This finding highlights the involvement of 
inflammation-induced citrullination in diabetes development and adds type 1 diabetes to the 
list of autoimmune diseases in which citrullination participates in disease pathogenesis, a list 
that includes rheumatoid arthritis (26,31,32), multiple sclerosis (33), lupus (30,34) and 
ulcerative colitis (27–29). This observation may have significant implications for the 
development of new therapeutic strategies to mitigate the progression and/or development of 
type 1 diabetes. 
We here provide evidence that the previously reported high expression of Padi2 in islets of 
NOD mice (5,16) originates from both the endocrine cells, including alpha- and beta-cells, as 
well as from the infiltrating immune cells, thereby conclusively demonstrating that beta-cells 
themselves have the capacity to citrullinate. This finding formed the basis for evaluating the 
effect of PAD inhibition in NOD mice. In the current treatment regimen, we started treatment 
at 8 weeks of age, a time point at which insulitis is already ongoing. The observation that 
inhibition of PAD activity, and thus citrullination, protected NOD mice against diabetes 
development suggests that citrullination may play a role in the amplification of the disease 
rather than being an initial trigger in breaking of immune tolerance. This strengthens our earlier 
findings of minor autoreactivity against citrullinated GRP78 in prediabetic NOD mice (5) and 
the increased occurrence of autoantibodies and autoreactive T-cell responses in long-standing 
T1D patients versus new onset patients (10). This view also fits well with the knowledge that 
citrullination is mostly associated with inflammation, thereby playing a role in several 
autoimmune diseases, where citrullination takes place in the inflamed target tissues (26–34). 
The low levels of citrullination in islets of C57Bl/6 mice further demonstrate that citrullination 
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is present already under physiological conditions, however, the degree of citrullination is 
markedly increased in NOD islets associated with immune infiltration. 
BB-Cl-amidine treatment is effective in decreasing overall levels of citrullination in the 
pancreas, as shown by Western blotting and quantitative LC-MS/MS. Of interest, the most 
significant reduction was measured for citrullinated GRP78. In line with this, the level of 
autoantibodies against citrullinated GRP78 is decreased in the circulation of BB-Cl-amidine 
treated NOD mice. Although autoantibodies are not thought to be pathogenic in type 1 diabetes, 
this finding underlines the important effect of BB-Cl-amidine on reducing the antigenicity of 
beta-cell proteins in the inflamed islet environment. 
Pan-PAD inhibitors are known to alter NET release (34–37). Neutrophils and NETosis are 
thought to play an important role in the initiation and perpetuation of type 1 diabetes (20,21,43). 
Here, we show that BB-Cl-amidine reduces spontaneous NET release ex vivo from bone 
marrow-derived neutrophils of NOD mice, a finding that may be linked to a decrease in 
citrullinated histone H3 levels. Indeed, citrullination of histone H3, mediated by activation of 
PADs in neutrophils, is an initiating factor for the formation of NETs (44), and has been shown 
to be reduced by PAD inhibition (36). Our results are in line with studies in lupus (30,34) and 
collagen-induced arthritis (37), demonstrating that reduced NETosis in response to PAD 
inhibition is associated with disease amelioration. 
Looking at the islet level, BB-Cl-amidine treatment resulted in only a marginal reduction of 
insulitis, whereas pancreatic insulin levels were preserved. However, we did observe a 
significant reduction in the percentage of CD4+ TEM cells and in the frequency of IFNγ-
producing CD4+ and CD8+ T cells in the pancreas of BB-Cl-amidine treated mice. The 
observed reduction in IFNγ production may reflect an impaired effector function of the 
infiltrating immune cells (45). These results suggest that the immune cell infiltrate in BB-Cl-
amidine treated mice is less aggressive (46).
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Our results on increased frequency of Treg in the blood and spleen demonstrate a peripheral 
effect of BB-Cl-amidine. Additionally, splenic IFNγ production of BB-Cl-amidine treated 
mice was significantly reduced. These results suggest a more regulatory environment that 
favors immune tolerance and prevents intensification of the immune assault. Also, with 
Th1/Th2 polarization thought to play a role in T1D pathogenesis, the significant increase in 
IL-4 and decrease in the IFNγ/IL-10 ratio in the circulation of BB-Cl-amidine treated mice 
supports this hypothesis. Of note, whether Th1/Th2 polarization is a cause rather than a 
consequence of disease development, is not fully established. In line with these findings, an 
induction of Th2 cells by BB-Cl-amidine has been shown in a mouse model of rheumatoid 
arthritis (31) and a direct effect of BB-Cl-amidine on enhancing the differentiation of Th2 
subsets through inhibition of GATA3 citrullination was demonstrated mechanistically by Sun 
et al. (47).
For the first time, a pan-PAD inhibitor was used in a very long treatment regimen (17 weeks), 
with no detrimental side effects observed. This, together with reported disease amelioration 
with the use of PAD inhibitors in other autoimmune models, opens the road to potential clinical 
therapeutic applications. However, since PADs also participate in physiological processes (11), 
such as gene regulation and nerve myelination, such therapeutic treatment regimens will need 
careful consideration. The recent development of specific PAD2 (48) and PAD4 (49) 
inhibitors, as well as reversible PAD inhibitors (50), may be a solution, but their efficacy to 
treat autoimmune diseases remains to be confirmed. Results from ongoing studies may further 
invite to consider PAD inhibition as a therapeutic strategy, not only for type 1 diabetes but also 
for other autoimmune diseases. 
In conclusion, treatment of NOD mice with BB-Cl-amidine resulted in complete diabetes 
prevention, associated with decreased protein citrullination, anti-citrulline autoantibody 
formation, NETosis, and in situ IFNγ responses. We postulate that these effects, combined with 
Page 19 of 68 Diabetes
20
the direct effect of PAD inhibition on T cells, might lead to a less aggressive inflammatory 
environment in the islets and in the periphery. Our findings align with previous reports that 
citrullination plays a pathogenic role in type 1 diabetes and demonstrate that PAD inhibition is 
an attractive target for clinical therapeutic applications in autoimmunity. 
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Figures legends
Figure 1 - Padi2 is expressed in immune, alpha- and beta-cells from NOD islets. A-C: 
mRNA expression level in pancreatic immune cells (Imm), alpha-cells and beta-cells for the 
leukocyte marker CD45 (A); alpha-cell marker glucagon (Glc) (B); beta-cell marker insulin 1 
(Ins1) (C); and Padi2 (D) (n = 3; 3 independent experiments were performed with one mouse 
per experiment). E: Representative immunohistochemical staining against citrulline in 
pancreas sections of C57Bl/6 and NOD mice (scale bar = 50µm). All sections where mounted 
on one slide to enable good comparison. Data in A–D are mean ± SEM and were analyzed by 
one-way ANOVA. **P<0.01, ***P<0.001 and ****P<0.0001.
Figure 2 - BB-Cl-amidine treatment prevents diabetes development in NOD mice and 
preserves pancreatic insulin production. A: Percentage of diabetes free NOD mice treated 
with DMSO or BB-Cl-amidine. Eight-week-old female littermate NOD mice were injected 
subcutaneously with vehicle (25% DMSO in PBS) or BB-Cl-amidine (1µg/g body weight) six 
times per week until 25 weeks of age and followed-up for diabetes development (n = 17-18 
mice per group; 2 independent cohorts were performed with at least eight mice per group per 
experiment). B: Pancreatic insulin content of 13-week-old NOD mice treated with DMSO or 
BB-Cl-amidine from 8-13 weeks of age (n = 8-10; two independent experiments were 
performed with 4-5 mice per group per experiment). C: Illustrative images of insulin staining 
in the pancreas of 13-week-old NOD mice treated from 8-13 weeks of age with DMSO or BB-
Cl-amidine (scale bar = 50µm). Data in A were evaluated by Kaplan-Meier survival analysis 
with Mantel-Cox log-rank test. Data in B are mean ± SEM and were analyzed by unpaired t-
test with Welch’s correction. **P<0.01 and ***P<0.001.
Figure 3 - BB-Cl-amidine treatment reduces citrullination in the pancreas and the 
formation of circulating autoantibodies. A: Representative immunohistochemical staining 
against citrulline in pancreas sections of 13-week-old DMSO or BB-Cl-amidine treated NOD 
mice (scale bar = 50µm). All sections where mounted on one slide to enable good comparison. 
B: Representative Western blot with anti-modified citrulline antibody in pancreatic lysates of 
13-week-old DMSO or BB-Cl-amidine treated NOD mice. C: Optical density ratio (sum of 
citrullinated bands/GAPDH band) of pancreas samples from DMSO or BB-Cl-amidine treated 
mice (n = 4 mice per group). D: Volcano plot showing significant fold changes in citrullinated 
proteins in pancreas of NOD mice treated with BB-Cl-amidine, from 8 until 13 weeks of age, 
compared to DMSO treated NOD mice. The x axis represents log2 expression fold changes 
(BB-Cl-amidine/DMSO), and the y axis represents the adjusted p-values (as -log10). E-F: 
Comparison between the serum levels of anti-citrullinated GRP78 antibodies in NOD mice, 
treated with DMSO or BB-Cl-amidine, at 13 weeks of age (E) and at 25 weeks of age (F) (n = 
9-17 samples per group; two independent experiments were performed, with at least two mice 
per group per experiment). Data in C, E and F are mean ± SEM and were analyzed by unpaired 
t-test with Welch’s correction. Data in D were analyzed by Mann-Whitney U test. *P<0.05 and 
**P<0.01.
Figure 4 - BB-Cl-amidine treatment reduces NET release. A-B: Bone marrow-derived 
neutrophils were isolated from 13-week-old NOD mice treated with DMSO or BB-Cl-amidine 
and cultured for 3h. Spontaneous NET formation was blindly evaluated by fluorescence 
microscopy. A: Representative images of spontaneous NETosis of bone marrow-derived 
neutrophils from DMSO or BB-Cl-amidine treated mice (scale bar = 10µm). White arrows 
point to NET forming cells. B: Percentage of NET formation was quantified blindly by 
fluorescence microscopy, after Hoechst staining (n = 10-15 mice per group; two independent 
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experiments were performed, with at least four mice per group per experiment). Each dot 
indicates the value for a single mouse. Data in B are mean ± SEM and were analyzed by 
unpaired t-test with Welch’s correction. *P<0.05.
Figure 5 – BB-Cl-amidine alters the phenotype of immune infiltrate in the islets. A: 
Insulitis score of 13-week-old NOD mice treated with vehicle (DMSO) or BB-Cl-amidine from 
8-13 weeks of age (n = 6 mice per group; two independent experiments were performed, with 
three mice per group per experiment). Score 0 (     ): intact islets; 1 (     ): peri-
insulitis; 2 (     ): <50% infiltration; 3 (      ): >50% infiltration; and 4 (      ): complete 
destruction. B-C: Immune cells isolated from the pancreas of 13-week-old DMSO or BB-Cl-
amidine treated NOD mice were stimulated in vitro with PMA and ionomycin in the presence 
of GolgiStop. Representative flow cytometry plots and percentage of IFN+ cells (%IFN+) in 
CD4+ (B) and CD8+ (C) T cells isolated from pancreas (n = 9-12 mice per group; two 
independent experiments were performed with at least three mice per group per experiment). 
D-F: Representative flow cytometry plots and percentage of Treg (CD4+ CD25+ Foxp3+) (D), 
CD4+ TEM (CD4+ Foxp3- CD44HIGH CD62L-) (E) and CD8+ TEM (CD8+ Foxp3- CD44HIGH 
CD62L-) (F) in pancreas of 13-week-old NOD mice treated with DMSO or BB-Cl-amidine (n 
= 15-16 mice per group; two independent experiments were performed with at least six mice 
per group per experiment). Data in B-F are mean ± SEM and were analyzed by unpaired t-test 
with Welch’s correction. *P<0.05 and **P<0.01. Treg, regulatory T cells; TEM, effector memory 
T cells.
Figure 6 - BB-Cl-amidine treatment is associated with a Th1 to Th2 shift in the periphery. 
A-D: Serum cytokine levels of IFNγ (A), IL-4 (B), IL-10 (C) and ratio IFNγ/IL-10 (D) in 13-
week-old NOD mice treated from 8-13 weeks with DMSO or BB-Cl-amidine (n = 28-35 mice 
per group; four independent experiments were performed with at least seven mice per group 
per experiment). E-H: Splenocytes isolated from the pancreas of 13-week-old DMSO or BB-
Cl-amidine treated NOD mice were stimulated in vitro with PMA and ionomycin in the 
presence of GolgiStop (n = 18-19 mice per group; two independent experiments were 
performed with at least eight mice per group per experiment). Cytokine production was 
measured by flow cytometry in CD4+ and CD8+ T cell populations considering the 2 following 
parameters: 1) percentage of IFN+ cells (%IFN+) and 2) fold change of the MFI of IFN in 
IFN+ cells (MFI IFN+). Per experiment, the geometric MFI of each sample was normalized 
to the average geometric MFI of the DMSO group. Representative flow cytometry plots and 
histograms depicting the geometric MFI of IFNγ between the two groups are shown above the 
pooled data. E-F: IFN+ (E) and MFI IFN+ (F) in splenic CD4+ T cells. G-H: %IFN+ (G) and 
MFI IFN+ (H) in splenic CD8+ T cells. Data in A-H are mean ± SEM and were analyzed by 
unpaired t-test with Welch’s correction. *P<0.05, **P<0.01 and ****P<0.0001. 
Figure 7 - BB-Cl-amidine increases the frequency of Treg cells in the periphery. 
Representative flow cytometry plots and percentage of Treg (CD4+ CD25+ Foxp3+), CD4+ TEM 
(CD4+ Foxp3- CD44HIGH CD62L-) and CD8+ TEM (CD8+ Foxp3- CD44HIGH CD62L-) in 
peripheral blood (A-C) and spleen (D-F) from 13-week-old NOD mice treated with DMSO or 
BB-Cl-amidine (n = 15-19 mice per group; two independent experiments were performed with 
at least six mice per group per experiment). Data in A-F are mean ± SEM and were analyzed 
by unpaired t-test with Welch’s correction. *P<0.05 and **P<0.01. Treg, regulatory T cell; TEM, 
effector memory T cell.
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Figure 1 - Padi2 is expressed in immune, alpha- and beta-cells from NOD islets. A-C: mRNA 
expression level in pancreatic immune cells (Imm), alpha-cells and beta-cells for the leukocyte marker CD45 
(A); alpha-cell marker glucagon (Glc) (B); beta-cell marker insulin 1 (Ins1) (C); and Padi2 (D) (n = 3; 3 
independent experiments were performed with one mouse per experiment). E: Representative 
immunohistochemical staining against citrulline in pancreas sections of C57Bl/6 and NOD mice (scale bar = 
50µm). All sections where mounted on one slide to enable good comparison. Data in A–D are mean ± SEM 
and were analyzed by one-way ANOVA. **P<0.01, ***P<0.001 and ****P<0.0001. 
121x104mm (600 x 600 DPI) 
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Figure 2 - BB-Cl-amidine treatment prevents diabetes development in NOD mice and preserves 
pancreatic insulin production. A: Percentage of diabetes free NOD mice treated with DMSO or BB-Cl-
amidine. Eight-week-old female littermate NOD mice were injected subcutaneously with vehicle (25% DMSO 
in PBS) or BB-Cl-amidine (1µg/g body weight) six times per week until 25 weeks of age and followed-up for 
diabetes development (n = 17-18 mice per group; 2 independent cohorts were performed with at least eight 
mice per group per experiment). B: Pancreatic insulin content of 13-week-old NOD mice treated with DMSO 
or BB-Cl-amidine from 8-13 weeks of age (n = 8-10; two independent experiments were performed with 4-5 
mice per group per experiment). C: Illustrative images of insulin staining in the pancreas of 13-week-old 
NOD mice treated from 8-13 weeks of age with DMSO or BB-Cl-amidine (scale bar = 50µm). Data in A were 
evaluated by Kaplan-Meier survival analysis with Mantel-Cox log-rank test. Data in B are mean ± SEM and 
were analyzed by unpaired t-test with Welch’s correction. **P<0.01 and ***P<0.001. 
172x54mm (600 x 600 DPI) 
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Figure 3 - BB-Cl-amidine treatment reduces citrullination in the pancreas and the formation of 
circulating autoantibodies. A: Representative immunohistochemical staining against citrulline in pancreas 
sections of 13-week-old DMSO or BB-Cl-amidine treated NOD mice (scale bar = 50µm). All sections where 
mounted on one slide to enable good comparison. B: Representative Western blot with anti-modified 
citrulline antibody in pancreatic lysates of 13-week-old DMSO or BB-Cl-amidine treated NOD mice. C: Optical 
density ratio (sum of citrullinated bands/GAPDH band) of pancreas samples from DMSO or BB-Cl-amidine 
treated mice (n = 4 mice per group). D: Volcano plot showing significant fold changes in citrullinated 
proteins in pancreas of NOD mice treated with BB-Cl-amidine, from 8 until 13 weeks of age, compared to 
DMSO treated NOD mice. The x axis represents log2 expression fold changes (BB-Cl-amidine/DMSO), and 
the y axis represents the adjusted p-values (as -log10). E-F: Comparison between the serum levels of anti-
citrullinated GRP78 antibodies in NOD mice, treated with DMSO or BB-Cl-amidine, at 13 weeks of age (E) 
and at 25 weeks of age (F) (n = 9-17 samples per group; two independent experiments were performed, 
with at least two mice per group per experiment). Data in C, E and F are mean ± SEM and were analyzed by 
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unpaired t-test with Welch’s correction. Data in D were analyzed by Mann-Whitney U test. *P<0.05 and 
**P<0.01. 
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Figure 4 - BB-Cl-amidine treatment reduces NET release. A-B: Bone marrow-derived neutrophils were 
isolated from 13-week-old NOD mice treated with DMSO or BB-Cl-amidine and cultured for 3h. Spontaneous 
NET formation was blindly evaluated by fluorescence microscopy. A: Representative images of spontaneous 
NETosis of bone marrow-derived neutrophils from DMSO or BB-Cl-amidine treated mice (scale bar = 10µm). 
White arrows point to NET forming cells. B: Percentage of NET formation was quantified blindly by 
fluorescence microscopy, after Hoechst staining (n = 10-15 mice per group; two independent experiments 
were performed, with at least four mice per group per experiment). Each dot indicates the value for a single 
mouse. Data in B are mean ± SEM and were analyzed by unpaired t-test with Welch’s correction. *P<0.05. 
172x59mm (600 x 600 DPI) 
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Figure 5 – BB-Cl-amidine alters the phenotype of immune infiltrate in the islets. A: Insulitis score of 
13-week-old NOD mice treated with vehicle (DMSO) or BB-Cl-amidine from 8-13 weeks of age (n = 6 mice 
per group; two independent experiments were performed, with three mice per group per experiment). Score 
0 (white): intact islets; 1 (vertical lines): peri-insulitis; 2 (grey): <50% infiltration; 3 (horizontal lines): 
>50% infiltration; and 4 (black): complete destruction. B-C: Immune cells isolated from the pancreas of 13-
week-old DMSO or BB-Cl-amidine treated NOD mice were stimulated in vitro with PMA and ionomycin in the 
presence of GolgiStop. Representative flow cytometry plots and percentage of IFNγ+ cells (%IFNγ+) in CD4+ 
(B) and CD8+ (C) T cells isolated from pancreas (n = 9-12 mice per group; two independent experiments 
were performed with at least three mice per group per experiment). D-F: Representative flow cytometry 
plots and percentage of Treg (CD4+ CD25+ Foxp3+) (D), CD4+ TEM (CD4+ Foxp3- CD44HIGH CD62L-) (E) and 
CD8+ TEM (CD8+ Foxp3- CD44HIGH CD62L-) (F) in pancreas of 13-week-old NOD mice treated with DMSO or 
BB-Cl-amidine (n = 15-16 mice per group; two independent experiments were performed with at least six 
mice per group per experiment). Data in B-F are mean ± SEM and were analyzed by unpaired t-test with 
Welch’s correction. *P<0.05 and **P<0.01. Treg, regulatory T cells; TEM, effector memory T cells. 
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Figure 6 - BB-Cl-amidine treatment is associated with a Th1 to Th2 shift in the periphery. A-D: 
Serum cytokine levels of IFNγ (A), IL-4 (B), IL-10 (C) and ratio IFNγ/IL-10 (D) in 13-week-old NOD mice 
treated from 8-13 weeks with DMSO or BB-Cl-amidine (n = 28-35 mice per group; four independent 
experiments were performed with at least seven mice per group per experiment). E-H: Splenocytes isolated 
from the pancreas of 13-week-old DMSO or BB-Cl-amidine treated NOD mice were stimulated in vitro with 
PMA and ionomycin in the presence of GolgiStop (n = 18-19 mice per group; two independent experiments 
were performed with at least eight mice per group per experiment). Cytokine production was measured by 
flow cytometry in CD4+ and CD8+ T cell populations considering the 2 following parameters: 1) percentage 
of IFNγ+ cells (%IFNγ+) and 2) fold change of the MFI of IFNγ in IFNγ+ cells (MFI IFNγ+). Per experiment, 
the geometric MFI of each sample was normalized to the average geometric MFI of the DMSO group. 
Representative flow cytometry plots and histograms depicting the geometric MFI of IFNγ between the two 
groups are shown above the pooled data. E-F: IFNγ+ (E) and MFI IFNγ+ (F) in splenic CD4+ T cells. G-H: 
%IFNγ+ (G) and MFI IFNγ+ (H) in splenic CD8+ T cells. Data in A-H are mean ± SEM and were analyzed by 
unpaired t-test with Welch’s correction. *P<0.05, **P<0.01 and ****P<0.0001. 
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Figure 7 - BB-Cl-amidine increases the frequency of Treg cells in the periphery. Representative flow 
cytometry plots and percentage of Treg (CD4+ CD25+ Foxp3+), CD4+ TEM (CD4+ Foxp3- CD44HIGH CD62L-) 
and CD8+ TEM (CD8+ Foxp3- CD44HIGH CD62L-) in peripheral blood (A-C) and spleen (D-F) from 13-week-
old NOD mice treated with DMSO or BB-Cl-amidine (n = 15-19 mice per group; two independent 
experiments were performed with at least six mice per group per experiment). Data in A-F are mean ± SEM 
and were analyzed by unpaired t-test with Welch’s correction. *P<0.05 and **P<0.01. Treg, regulatory T 
cell; TEM, effector memory T cell. 
147x162mm (600 x 600 DPI) 
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Supplementary Figure 1 – Negative staining controls for immunohistochemistry with anti-citrulline 
antibody. Representative immunohistochemistry images of the negative control staining. The negative 
control was performed by omitting the primary anti-citrulline antibody in pancreas sections of C57Bl/6 
and NOD mice (shown in Figure 1 of the manuscript). All sections where mounted on one slide to 
enable good comparison (scale bar = 50µm).
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Supplementary Figure 2 – BB-Cl-amidine treatment does not alter body weight in NOD mice. Eight-
week-old female littermate NOD mice were injected subcutaneously with vehicle (25% DMSO in PBS) 
or BB-Cl-amidine (1µg/g body weight) six times per week until 25 weeks of age. Body weight of NOD 
mice treated with DMSO or BB-Cl-amidine (n = 17-18 mice per group; 2 independent cohorts were 
performed with at least eight mice per group per experiment). 
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Supplementary Figure 3 – Negative staining controls for immunohistochemistry with anti-citrulline 
antibody. Representative immunohistochemistry images of the negative control staining. The negative 
control was performed by omitting the primary anti-citrulline antibody in pancreas sections of 13-
week-old NOD mice treated with DMSO or BB-Cl-amidine from 8-13 weeks of age (shown in Figure 3 
of the manuscript). All sections where mounted on one slide to enable good comparison (scale bar = 
50µm).
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Supplementary Figure 4 – Gating strategy for T cell phenotyping. Gating strategy for T cell 
phenotyping in the pancreas (A), blood (B) and spleen (C). Left panels show the gating strategy for 
obtaining live CD3+ T cells. Top right panel shows gating strategy for obtaining Treg (CD4+ CD25+ Foxp3+) 
cells. Bottom right panels show gating strategy for obtaining CD4+ TEM (CD4+ Foxp3- CD44HIGH CD62L-), 
CD4+ TCM (CD4+ Foxp3- CD44HIGH CD62L+) and CD4+ Tnaïve (CD4+ Foxp3- CD44LOW CD62L+). CD8+ TEM (CD8+ 
Foxp3- CD44HIGH CD62L-), CD8+ TCM (CD8+ Foxp3- CD44HIGH CD62L+) and CD8+ Tnaïve (CD8+ Foxp3- CD44LOW 
CD62L+) are obtained in the same way as CD4+, but in the CD8+ gate (not shown). Plots are 
representative of 2 independent experiments (n = 15-19), with at least six mice per group per 
experiment. ZY, Zombie Yellow; Treg, regulatory T cells; TEM, effector memory T cells; TCM, central 
memory T cells.
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Supplementary Figure 5 – Phenotype of pancreatic T cells. A-D: Percentage of CD4+ Tnaïve (CD4+ Foxp3- 
CD44LOW CD62L+) (A), CD4+ TCM (CD4+ Foxp3- CD44HIGH CD62L+) (B), CD8+ Tnaïve (CD8+ Foxp3- CD44LOW 
CD62L+) (C) and CD8+ TCM (CD8+ Foxp3- CD44HIGH CD62L+) (D) in the pancreas of 13-week-old NOD mice 
treated with DMSO or BB-Cl-amidine (n = 15-16 mice per group; two independent experiments were 
performed with at least six mice per group per experiment). TCM, central memory T cell.  
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Supplementary Figure 6 – Phenotype of peripheral T cells. Percentage of CD4+ Tnaïve (CD4+ Foxp3- 
CD44LOW CD62L+), CD4+ TCM (CD4+ Foxp3- CD44HIGH CD62L+), CD8+ Tnaïve (CD8+ Foxp3- CD44LOW CD62L+) 
and CD8+ TCM (CD8+ Foxp3- CD44HIGH CD62L+) in different organs of 13-week-old NOD mice treated with 
DMSO or BB-Cl-amidine (n = 15-19 mice per group; two independent experiments were performed 
with at least six mice per group per experiment). A-D: Frequency of CD4+ Tnaïve (A), CD4+ TCM (B), CD8+ 
Tnaïve (C) and CD8+ TCM (D) in peripheral blood. E-H: Frequency of CD4+ Tnaïve (E), CD4+ TCM (F), CD8+ Tnaïve 
(G) and CD8+ TCM (H) in spleen. *P<0.05 and **P<0.01. TCM, central memory T cell.    
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Isolation of pancreatic islets
For isolation of NOD adult islets 0.5mg/ml collagenase P (Sigma) diluted in HBSS (Thermo 
Fisher) was injected in the main pancreatic duct while the ampulla of Vater was clamped. Next, 
the pancreas was collected and incubated in 0.5mg/ml collagenase P at 37°C for 11min. Islets 
were handpicked and cultured overnight in RPMI 1640 (Thermo Fisher) supplemented with 
10% (vol/vol) Fetal Bovine Serum (FBS) (Biowest).
Flow cytometry sorting
Islets were dispersed into single-cell suspensions by incubation for 90sec at 37°C in 0.025% 
trypsin-EDTA (Thermo Fisher). Similarly as previously described (1), for cell surface staining, 
cells were incubated with antibodies at 4°C for 15min in the dark in FACS medium (HBSS + 
2% FBS), rinsed in FACS medium and resuspended in FACS medium with propidium iodide 
(1/4000, Sigma) before FACS acquisition and sorting. The following antibodies were used: 
EpCam-BV605 (G8.8, Biolegend BLE118227), CD31-PercpCy5.5 (MEC13.3, Biolegend 
BLE102522), CD45-PercpCy5.5 (30-F11, Biolegend BLE103132), CD24-APC-Fire 750 
(MA/69, Biolegend BLE101840), CD49f-PE (GoH3, Biolegend BLE313612), CD71-FITC 
(RI7217, Biolegend BLE113806), TER-119-PercpCy5.5 (TER-119, Biolegend BLE116228), 
TCRb-PECy7 (H57-597, Biolegend BLE109222), CD4-APC (GK1.5, Biolegend BLE100412), 
CD44-BV421 (IM7, BD Biosciences # 563970). For each antibody, optimal dilution was 
determined by titration. Cell sorting was carried out using a FACSAria III (BD). Data were 
analyzed using FlowJo 9.9.4 (RRID: SCR_008520). Dead cells were excluded from analyses 
using propidium iodide (fluorescence in both PE-A and PercpCy5.5-A channels, exclusion of 
the diagonal) and non-pancreatic lineages were excluded using the pan-hematopoietic marker 
CD45, the erythroid marker TER119, and the endothelial marker CD31. Pancreatic alpha- and 
beta-enriched fractions were isolated as described previously. As we determined that more than 
95% of Lin+ cells are CD45+, sorted Lin+ were considered as CD45+ cells. For qPCR cells 
were collected directly in Buffer RLT for qPCR (Qiagen).
Quantitative RT-PCR
RNA was isolated with the RNeasy Micro Kit (Qiagen) and RNA sample was reverse-
transcribed using the Maxima First Strand cDNA Synthesis Kit (Thermo Fisher) and a Biometra 
T3 Thermocycler (Analytik Jena). All kits were used per the manufacturer’s instructions. SYBR 
green qPCR was performed on a QuantStudio 3 (Thermo Fisher) per the manufacturer's 
instructions.
Proteomic analysis making use of biotin-phenylglyoxal labeling 
DMSO (n=4) and BB-Cl-amidine treated (n=4) mice pancreata were pooled in buffer (50mM 
HEPES pH 7.6, 0.5% NP40 and 1mM PMSF) and homogenized using a tissue homogenizer 
(20sec with maximum speed with 10min time interval three times). The lysed tissue samples 
were centrifuged (12,000rpm, 30min) at 4°C. The supernatants were isolated, and the protein 
concentration was determined using the DC™ (detergent compatible) assay. Equal protein 
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concentrations from DMSO and BB-Cl-amidine treated samples were labeled with biotin-
phenylglyoxal (biotin-PG) in quadruplicate as previously described (2). Briefly, supernatants 
from DMSO and BB-Cl-amidine treated samples (300μg) were diluted in buffer (100mM 
HEPES pH 7.6) to a final concentration of 1μg/μL in a reaction volume of 300μL and incubated 
with 20% trichloroacetic acid (60μL of 100% TCA) and 0.5mM biotin-PG (5μL of 5mM stock) 
for 30min at 37°C. After a 30min incubation, the reaction was quenched with 60μL of 0.1M 
citrulline dissolved in 50mM HEPES pH 7.6. Proteins were precipitated by placing the reaction 
mixtures on ice for 30min followed by centrifugation (13,500rpm, 15min) at 4°C. The 
supernatants were discarded, and the protein pellet was washed twice with cold acetone and 
dried.
Protein pellets were then resuspended in 1.2% SDS in PBS, boiled for 10min and sonicated for 
12-15min. Once dissolved, samples were diluted in PBS buffer (0.2% final SDS concentration) 
and incubated with streptavidin agarose slurry (170μL) overnight at 4°C, and a further 3h at 
25°C. Streptavidin beads were then washed with PBS containing 0.2% SDS (1X), with PBS 
alone (3X), and water (3X) in order to remove any unbound proteins. Streptavidin beads were 
heated in a buffer containing 500μL of 6M urea in PBS and 10mM DTT (65°C, 20min) followed 
by iodoacetamide (20mM) addition and further incubation for 30min at 37°C. The beads were 
pelleted by centrifugation (1,400 x g for 3min), resuspended in a premixed solution of 2M urea, 
1mM CaCl2 and 2μg trypsin in PBS and incubated overnight at 37°C. The beads were then 
pelleted by centrifugation and the supernatant, containing the peptide digests, was collected. 
The pellet was washed twice with water (50μL) and the collected supernatant fractions were 
combined. Formic acid (15μL) was added to the peptide mixture.
TMT labeling of tryptic digest
A total of eight peptide digests were obtained from quadruplicate labeling of the DMSO and 
BB-Cl-amidine treated samples. These samples were subjected to desalting using commercially 
available Pierce C18 Spin columns (Thermo Fisher) to remove buffer components that may 
interfere with TMT labeling. The desalting procedure followed the manufacturer’s protocol.  
Peptide concentration was determined before as well as after desalting using the commercially 
available Pierce Quantitative Colorimetric Peptide Assay kit (Thermo Fisher) to ensure that the 
peptides were not lost during the desalting procedure. The samples were then evaporated to 
dryness in a Speedvac.  The eight peptide digests were then labeled using a commercially 
available TMT labeling system (Thermo Fisher). Briefly, the samples were resuspended in 
100mM HEPES pH 8.6 (100µL) in eight different Eppendorf tubes and treated with 8µL of 
TMT10plex labeling reagent. The samples were incubated for 1h at RT. The reaction was 
further quenched using 2.5µL of 5% hydroxylamine and samples were further incubated for 
15min at RT. After quenching excess TMT reagent, the TMT-labeled samples (90µL) from 
each tube were mixed together in a separate Eppendorf tube. The combined sample were 
evaporated to dryness in a Speedvac and then stored at -80°C until mass spectrometry (MS) 
analysis.
LC-MS/MS and Data Processing
Liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed on a 
NanoAcquity UPLC (Waters Corporation) coupled to an Orbitrap Fusion Lumos Tribrid 
(Thermo Fisher) mass spectrometer, operating in the positive ion mode (1.4kV, applied by 
liquid junction). Mobile phases were A (0.1% (v/v) formic acid in water) and B (0.1% (v/v) 
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formic acid in acetonitrile). The peptides were reconstituted in 35µL of 5% (v/v) acetonitrile, 
0.1% (v/v) formic acid in water, and 3.8µL was injected in 5% B at 4µL/min for 4min to a 
100µm ID fused-silica pre-column (Kasil frit) packed with 2cm of ProntoSIL C18 AQ (Bischoff 
Chromatography, 200Å, 5µm) particles. Peptides were then separated and eluted at 300nL/min 
by an in-house packed fused silica analytical column (gravity-pulled tip) packed with 25cm 
Magic C18AQ (Bruker-Michrom, 100Å, 3µm) particles. In brief, the gradient was 10-35% B 
(0-100min); 35-65% B (100-120min); 95% B (121-126min), 5% B (127-140min). Mass spectra 
were acquired in the Orbitrap mass analyzer using a resolution of 60,000 (m/z 200), an ion target 
population of 7e5, and maximum ion injection time of 30msec. Tandem mass spectra were 
acquired using data dependent acquisition using the following parameters: cycle time, 2sec; 
intensity threshold, 2e4; isolation width, 0.8Da; HCD collision energy, 38%; resolution, 30,000; 
ion population, 1e5; maximum ion injection time,110 msec.
The raw data were processed using Proteome Discoverer (Thermo Fisher, version 2.1.1.21) and 
searched against SwissProt murine (downloaded 07/2019) database using Mascot (Matrix 
Science, version 2.6.2). The mass tolerance was 10ppm for precursor and 0.05Da for the 
fragment ions. Full tryptic cleavages were considered along with static modifications of 
carbamidomethylation (cysteine), TMT labelling (peptide N-terminal and lysine) and dynamic 
modifications of acetylation (protein N-terminal), oxidation (methionine) and glutamine to 
pyroglutamate conversion (peptide N-terminal). Peptides were assembled to proteins using 
Scaffold (Proteome Software, version 4.11.0) and were filtered to a 1% FDR using Peptide 
Prophet (3). The protein threshold was set to 99% probability using Protein Prophet (4) and 
only proteins with 2 or more filtered peptides were considered. The data was further processed 
by Scaffold Q+S (4.11.0) for quantitative analysis.
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Supplementary Table 1. Differentially regulated citrullinated 
proteins in pancreas of BB-Cl-amidine treated versus DMSO 
treated NOD mice
* P<0.05 (Log10p-value = 1.122)
 Log2Ratio Log10p-value (*) Accession
1 -1.606163 1.3050913 sp|Q8BU14|SEC62_MOUSE
2 -1.5756054 2.4036503 sp|Q8CAQ8-2|MIC60_MOUSE
3 -1.5686817 2.758175 sp|P47915|RL29_MOUSE
4 -1.5622921 3.109283 sp|P35564|CALX_MOUSE
5 -1.5391521 1.3050913 sp|Q9ERG0-2|LIMA1_MOUSE
6 -1.5389996 3.4577034 sp|Q9D0F3|LMAN1_MOUSE
7 -1.5316582 15.25562 sp|P08113|ENPL_MOUSE
8 -1.5246878 4.14842 sp|Q60997-2|DMBT1_MOUSE
9 -1.5179377 11.206782 sp|Q64285|CEL_MOUSE
10 -1.5131435 1.6794106 sp|Q9Z0Y2|PA21B_MOUSE
11 -1.5123882 1.6794106 sp|Q6ZQ58|LARP1_MOUSE
12 -1.5034275 3.109283 sp|P47963|RL13_MOUSE
13 -1.4920053 5.8520784 sp|P27659|RL3_MOUSE
14 -1.4888325 2.4036503 sp|Q8BKC5|IPO5_MOUSE
15 -1.4820528 1.3050913 sp|Q8C0D5|EFL1_MOUSE
16 -1.4796295 1.3050913 sp|Q3U0V1|FUBP2_MOUSE
17 -1.4736061 1.6794106 sp|P13020-2|GELS_MOUSE
18 -1.4711285 14.724141 sp|Q78PY7|SND1_MOUSE
19 -1.4627047 1.3050913 sp|P26043|RADI_MOUSE
20 -1.460556 2.044628 sp|Q8BI84-3|TGO1_MOUSE
21 -1.45401 11.539065 sp|Q9JKR6|HYOU1_MOUSE
22 -1.4527073 9.2091 sp|Q9D8E6|RL4_MOUSE
23 -1.4449883 4.8330717 sp|Q8BM55|TM214_MOUSE
24 -1.4447136 5.17366 sp|Q9Z1Z0|USO1_MOUSE
25 -1.4443893 3.8039558 sp|Q8VEK3-2|HNRPU_MOUSE
26 -1.4433832 1.6794106 sp|Q9CQX2|CYB5B_MOUSE
27 -1.4416866 14.778499 sp|Q8VDJ3|VIGLN_MOUSE
28 -1.4405212 10.541792 sp|P08003|PDIA4_MOUSE
29 -1.4388752 1.3050913 sp|P62911|RL32_MOUSE
30 -1.4383736 5.8520784 sp|P62754|RS6_MOUSE
31 -1.4367504 3.8039558 sp|Q8R1B4|EIF3C_MOUSE
32 -1.4338951 6.527502 sp|Q99PL5|RRBP1_MOUSE
33 -1.4318275 7.5362897 sp|Q8VDD5|MYH9_MOUSE
34 -1.4302464 3.109283 sp|P84099|RL19_MOUSE
35 -1.4291286 2.4036503 sp|Q7TPR4|ACTN1_MOUSE
36 -1.4274426 4.4913836 sp|P47911|RL6_MOUSE
37 -1.4266815 6.527502 sp|Q7TPZ8|CBPA1_MOUSE
Page 48 of 68Diabetes
SUPPLEMENTARY DATA
13
38 -1.4237385 2.758175 sp|Q91ZV0-3|MIA2_MOUSE
39 -1.4216404 5.5132895 sp|P12970|RL7A_MOUSE
40 -1.4201832 1.3050913 sp|Q4PJX1|ODR4_MOUSE
41 -1.420105 1.6794106 sp|Q99LM2|CK5P3_MOUSE
42 -1.4167576 3.8039558 sp|Q8VIJ6|SFPQ_MOUSE
43 -1.416626 3.109283 sp|P41105|RL28_MOUSE
44 -1.4158173 1.6794106 sp|Q9Z1D1|EIF3G_MOUSE
45 -1.4133005 10.541792 sp|P23116|EIF3A_MOUSE
46 -1.4126663 2.758175 sp|Q9D733|GP2_MOUSE
47 -1.4123726 1.3050913 sp|P61514|RL37A_MOUSE
48 -1.4122839 13.544657 sp|D3Z6P0-2|PDIA2_MOUSE
49 -1.4114666 >20 sp|P20029|BIP_MOUSE
50 -1.4096727 1.6794106 sp|Q8VE88-2|F1142_MOUSE
51 -1.4092903 1.3050913 sp|Q9JHU9|INO1_MOUSE
52 -1.4076557 6.527502 sp|Q99MR8|MCCA_MOUSE
53 -1.407486 9.2091 sp|P14211|CALR_MOUSE
54 -1.4055767 1.3050913 sp|Q64514-2|TPP2_MOUSE
55 -1.4040947 2.758175 sp|Q9DB77|QCR2_MOUSE
56 -1.4026165 1.6794106 sp|Q3U1J4|DDB1_MOUSE
57 -1.4025726 4.4913836 sp|Q8BMA6|SRP68_MOUSE
58 -1.4007816 3.109283 sp|Q6ZQ38|CAND1_MOUSE
59 -1.4003506 4.14842 sp|Q61035|SYHC_MOUSE
60 -1.39781 1.3050913 sp|O08553|DPYL2_MOUSE
61 -1.3975468 2.4036503 sp|P70168|IMB1_MOUSE
62 -1.3956604 1.3050913 sp|P97449|AMPN_MOUSE
63 -1.3956413 1.6794106 sp|P97379-2|G3BP2_MOUSE
64 -1.3956404 2.044628 sp|Q8VCT4|CES1D_MOUSE
65 -1.3933754 2.044628 sp|Q3TXS7|PSMD1_MOUSE
66 -1.3922386 3.4577034 sp|Q9CZM2|RL15_MOUSE
67 -1.3906231 1.3050913 sp|Q9CYA0|CREL2_MOUSE
68 -1.3901138 2.044628 sp|O08795-2|GLU2B_MOUSE
69 -1.3888931 3.4577034 sp|Q99L45|IF2B_MOUSE
70 -1.387639 1.3050913 sp|Q8VDM4|PSMD2_MOUSE
71 -1.3873711 3.4577034 sp|P62918|RL8_MOUSE
72 -1.3868294 3.4577034 sp|Q8K2B3|SDHA_MOUSE
73 -1.3841171 4.8330717 sp|Q60864|STIP1_MOUSE
74 -1.3825274 11.870765 sp|Q8K009|AL1L2_MOUSE
75 -1.3819504 1.3050913 sp|P19783|COX41_MOUSE
76 -1.3817673 5.8520784 sp|O55029|COPB2_MOUSE
77 -1.3795776 4.8330717 sp|Q61941|NNTM_MOUSE
78 -1.3793259 11.870765 sp|Q02053|UBA1_MOUSE
79 -1.3792286 5.8520784 sp|Q6P5E4|UGGG1_MOUSE
80 -1.3786354 6.864285 sp|Q91YW3|DNJC3_MOUSE
81 -1.3778496 >20 sp|P58252|EF2_MOUSE
82 -1.3770294 3.4577034 sp|Q60597-2|ODO1_MOUSE
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83 -1.3759804 4.8330717 sp|Q8VDN2|AT1A1_MOUSE
84 -1.3738422 1.6794106 sp|Q69ZS7-2|HBS1L_MOUSE
85 -1.3731365 1.6794106 sp|Q9CY27|TECR_MOUSE
86 -1.3721466 7.2005315 sp|P62242|RS8_MOUSE
87 -1.3701077 4.14842 sp|P57780|ACTN4_MOUSE
88 -1.3683395 2.044628 sp|Q61937|NPM_MOUSE
89 -1.3667011 4.4913836 sp|Q504N0|CBPA2_MOUSE
90 -1.3636742 2.044628 sp|Q8R146-2|APEH_MOUSE
91 -1.3631992 1.3050913 sp|P45700|MA1A1_MOUSE
92 -1.3621225 4.4913836 sp|Q61316|HSP74_MOUSE
93 -1.3612518 2.044628 sp|Q8BWW4|LARP4_MOUSE
94 -1.3611755 2.758175 sp|Q6P1B1|XPP1_MOUSE
95 -1.360982 1.6794106 sp|P46935|NEDD4_MOUSE
96 -1.3584862 4.14842 sp|P42932|TCPQ_MOUSE
97 -1.3582964 2.758175 sp|Q9WVE8|PACN2_MOUSE
98 -1.3576298 7.2005315 sp|O55143|AT2A2_MOUSE
99 -1.3571434 1.6794106 sp|P34022|RANG_MOUSE
100 -1.3570337 1.3050913 sp|Q8R010|AIMP2_MOUSE
101 -1.3560905 9.2091 sp|P29341|PABP1_MOUSE
102 -1.3555489 8.20651 sp|Q922D8|C1TC_MOUSE
103 -1.3548622 3.4577034 sp|Q99K01-2|PDXD1_MOUSE
104 -1.3539143 5.17366 sp|Q9ER72-2|SYCC_MOUSE
105 -1.3538799 5.8520784 sp|Q9Z1Q9|SYVC_MOUSE
106 -1.3524313 3.8039558 sp|Q921G7|ETFD_MOUSE
107 -1.350872 2.4036503 sp|Q9WUM5|SUCA_MOUSE
108 -1.3487844 5.17366 sp|Q9DBG7|SRPRA_MOUSE
109 -1.3481827 1.3050913 sp|P10630-2|IF4A2_MOUSE
110 -1.3480272 1.3050913 sp|O08529|CAN2_MOUSE
111 -1.3476143 5.17366 sp|P07901|HS90A_MOUSE
112 -1.3463306 1.3050913 sp|P62900|RL31_MOUSE
113 -1.3462315 2.758175 sp|Q9Z2I9|SUCB1_MOUSE
114 -1.3461132 9.875973 sp|P63017|HSP7C_MOUSE
115 -1.3459053 4.14842 sp|P19253|RL13A_MOUSE
116 -1.3458977 5.5132895 sp|Q99K67|AASS_MOUSE
117 -1.3458471 1.3050913 sp|P62960|YBOX1_MOUSE
118 -1.3456907 2.044628 sp|P19096|FAS_MOUSE
119 -1.3452873 3.109283 sp|Q80X90|FLNB_MOUSE
120 -1.3451614 2.4036503 sp|P46460|NSF_MOUSE
121 -1.3440971 5.17366 sp|P50580|PA2G4_MOUSE
122 -1.3432941 2.758175 sp|Q60854|SPB6_MOUSE
123 -1.3426933 2.758175 sp|Q93092|TALDO_MOUSE
124 -1.3426638 1.3050913 sp|Q6NZC7|S23IP_MOUSE
125 -1.3417797 5.5132895 sp|Q08642|PADI2_MOUSE
126 -1.3408585 9.2091 sp|P63038|CH60_MOUSE
127 -1.3408566 1.3050913 sp|Q99KB8-2|GLO2_MOUSE
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128 -1.3404121 1.3050913 sp|P99024|TBB5_MOUSE
129 -1.3401604 2.044628 sp|P09405|NUCL_MOUSE
130 -1.3398399 2.044628 sp|Q8BJ64|CHDH_MOUSE
131 -1.3393288 4.8330717 sp|Q91VD9|NDUS1_MOUSE
132 -1.3380337 3.109283 sp|Q922Q1|MARC2_MOUSE
133 -1.3370905 1.3050913 sp|Q99J99|THTM_MOUSE
134 -1.3368435 7.2005315 sp|Q99MN1|SYK_MOUSE
135 -1.3365211 7.5362897 sp|P25444|RS2_MOUSE
136 -1.3362446 8.541041 sp|Q8BH04|PCKGM_MOUSE
137 -1.3361301 4.14842 sp|P62717|RL18A_MOUSE
138 -1.3357277 4.14842 sp|Q76MZ3|2AAA_MOUSE
139 -1.3349895 6.1901226 sp|P11499|HS90B_MOUSE
140 -1.3349838 6.1901226 sp|Q8C1A5|THOP1_MOUSE
141 -1.3348017 1.3050913 sp|Q8BH24|TM9S4_MOUSE
142 -1.3339005 2.044628 sp|Q8BHN3-2|GANAB_MOUSE
143 -1.3320112 7.2005315 sp|Q921I1|TRFE_MOUSE
144 -1.3313932 1.3050913 sp|Q9CXI5|MANF_MOUSE
145 -1.3310795 1.3050913 sp|Q6IRU5-2|CLCB_MOUSE
146 -1.3307247 4.4913836 sp|Q8JZQ9|EIF3B_MOUSE
147 -1.329732 5.17366 sp|Q9CZ13|QCR1_MOUSE
148 -1.3291674 2.044628 sp|Q8BJW6|EIF2A_MOUSE
149 -1.3288612 4.14842 sp|Q9DBG6|RPN2_MOUSE
150 -1.3288498 1.3050913 sp|P47757-2|CAPZB_MOUSE
151 -1.3287697 4.8330717 sp|P61222|ABCE1_MOUSE
152 -1.3275337 2.044628 sp|Q91WD5|NDUS2_MOUSE
153 -1.3272305 1.6794106 sp|Q3V3R1|C1TM_MOUSE
154 -1.3262081 11.206782 sp|P27773|PDIA3_MOUSE
155 -1.3258724 3.109283 sp|Q9JKF1|IQGA1_MOUSE
156 -1.325594 3.4577034 sp|P62267|RS23_MOUSE
157 -1.3255043 5.5132895 sp|Q9Z110-2|P5CS_MOUSE
158 -1.3244228 2.4036503 sp|Q9R111|GUAD_MOUSE
159 -1.3243294 5.17366 sp|P16331|PH4H_MOUSE
160 -1.323288 10.209015 sp|Q05920|PYC_MOUSE
161 -1.3188515 3.8039558 sp|E9PVA8|GCN1_MOUSE
162 -1.3182621 3.109283 sp|P16332|MUTA_MOUSE
163 -1.318121 4.14842 sp|Q61768|KINH_MOUSE
164 -1.3170776 3.109283 sp|Q91VR5|DDX1_MOUSE
165 -1.3169403 4.14842 sp|Q8VE47|UBA5_MOUSE
166 -1.3169346 1.3050913 sp|P13439|UMPS_MOUSE
167 -1.3159828 1.3050913 sp|Q8R4N0|CLYBL_MOUSE
168 -1.3152256 2.044628 sp|Q8CGK3|LONM_MOUSE
169 -1.3147907 1.3050913 sp|O35295|PURB_MOUSE
170 -1.314601 1.3050913 sp|Q3THS6|METK2_MOUSE
171 -1.3144493 3.4577034 sp|Q8BP67|RL24_MOUSE
172 -1.3129902 5.5132895 sp|Q8BU30|SYIC_MOUSE
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173 -1.3128166 1.3050913 sp|Q8R081|HNRPL_MOUSE
174 -1.312418 9.875973 sp|P40142|TKT_MOUSE
175 -1.3121223 5.8520784 sp|Q9QZE5|COPG1_MOUSE
176 -1.312088 1.3050913 sp|Q5FWK3|RHG01_MOUSE
177 -1.3116188 5.17366 sp|P17892|LIPR2_MOUSE
178 -1.3114376 1.3050913 sp|Q60931|VDAC3_MOUSE
179 -1.3113327 3.109283 sp|Q64727|VINC_MOUSE
180 -1.311204 2.758175 sp|P56399|UBP5_MOUSE
181 -1.310852 3.8039558 sp|Q8BGD9|IF4B_MOUSE
182 -1.3106852 3.109283 sp|Q9D8U3|ERP27_MOUSE
183 -1.3085461 5.8520784 sp|Q8R2E9|ERO1B_MOUSE
184 -1.3082428 2.758175 sp|Q9R0N0|GALK1_MOUSE
185 -1.3080387 13.879043 sp|Q8CGC7|SYEP_MOUSE
186 -1.3077297 8.87523 sp|Q99KI0|ACON_MOUSE
187 -1.3073292 1.3050913 sp|Q9EQH3|VPS35_MOUSE
188 -1.3064976 1.6794106 sp|Q99K23|UFSP2_MOUSE
189 -1.3062477 2.4036503 sp|O08807|PRDX4_MOUSE
190 -1.3061066 5.17366 sp|Q6ZWX6|IF2A_MOUSE
191 -1.3054523 3.8039558 sp|Q9CPR4|RL17_MOUSE
192 -1.3040752 8.20651 sp|Q8BGQ7|SYAC_MOUSE
193 -1.3038893 1.3050913 sp|A2ALS5-3|RPGP1_MOUSE
194 -1.3038769 1.3050913 sp|Q61712|DNJC1_MOUSE
195 -1.3026886 1.6794106 sp|Q62433|NDRG1_MOUSE
196 -1.301486 5.8520784 sp|Q8BMJ2|SYLC_MOUSE
197 -1.3014832 1.6794106 sp|Q9EPJ9-2|ARFG1_MOUSE
198 -1.3013763 5.5132895 sp|P10852|4F2_MOUSE
199 -1.3013611 4.14842 sp|Q9WU78-3|PDC6I_MOUSE
200 -1.300457 3.109283 sp|P31230|AIMP1_MOUSE
201 -1.3002872 3.109283 sp|P50136|ODBA_MOUSE
202 -1.3000164 3.4577034 sp|Q9Z0X1|AIFM1_MOUSE
203 -1.2996407 1.6794106 sp|P45952|ACADM_MOUSE
204 -1.2996159 3.109283 sp|P46978|STT3A_MOUSE
205 -1.2995377 4.8330717 sp|P80313|TCPH_MOUSE
206 -1.2984924 >20 sp|P09103|PDIA1_MOUSE
207 -1.2976894 2.044628 sp|Q99JY9|ARP3_MOUSE
208 -1.2975521 6.527502 sp|P80318|TCPG_MOUSE
209 -1.2969227 1.3050913 sp|Q64324|STXB2_MOUSE
210 -1.2958546 2.4036503 sp|Q9CR57|RL14_MOUSE
211 -1.2954254 5.5132895 sp|Q6NZJ6|IF4G1_MOUSE
212 -1.2949848 3.8039558 sp|Q7TSV4|PGM2_MOUSE
213 -1.2946405 5.17366 sp|Q7TMK9-2|HNRPQ_MOUSE
214 -1.2941017 7.2005315 sp|Q8R0Y6|AL1L1_MOUSE
215 -1.2937813 2.4036503 sp|Q8VCT3|AMPB_MOUSE
216 -1.2937784 4.14842 sp|P80316|TCPE_MOUSE
217 -1.2931099 15.4774685 sp|Q01853|TERA_MOUSE
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218 -1.2930288 1.3050913 sp|Q9CXR1|DHRS7_MOUSE
219 -1.291956 5.17366 sp|Q91WT9-2|CBS_MOUSE
220 -1.291832 4.4913836 sp|Q9JK88|SPI2_MOUSE
221 -1.2915516 9.875973 sp|Q6P8U6|LIPP_MOUSE
222 -1.2909584 3.4577034 sp|Q5SUR0|PUR4_MOUSE
223 -1.2907934 4.4913836 sp|P28271|ACOC_MOUSE
224 -1.2906647 4.8330717 sp|Q9CWJ9|PUR9_MOUSE
225 -1.2903461 1.6794106 sp|Q9DB25|ALG5_MOUSE
226 -1.2898369 4.8330717 sp|O70194|EIF3D_MOUSE
227 -1.2889051 5.17366 sp|Q91V92|ACLY_MOUSE
228 -1.2882395 5.5132895 sp|P80314|TCPB_MOUSE
229 -1.2875557 3.8039558 sp|Q8CHT0|AL4A1_MOUSE
230 -1.28619 5.17366 sp|Q9JHU4|DYHC1_MOUSE
231 -1.2860632 9.875973 sp|Q03265|ATPA_MOUSE
232 -1.2860603 4.8330717 sp|Q9D8S3|ARFG3_MOUSE
233 -1.2857866 2.4036503 sp|Q9DCX2|ATP5H_MOUSE
234 -1.2849884 1.6794106 sp|O88487|DC1I2_MOUSE
235 -1.2849503 1.6794106 sp|P68372|TBB4B_MOUSE
236 -1.2847481 6.527502 sp|Q5XJY5|COPD_MOUSE
237 -1.2844143 2.044628 sp|Q9Z1Z2|STRAP_MOUSE
238 -1.2842455 7.5362897 sp|P26638|SYSC_MOUSE
239 -1.2839375 1.3050913 sp|Q8VBV7|CSN8_MOUSE
240 -1.2835426 6.864285 sp|P38647|GRP75_MOUSE
241 -1.2834921 2.044628 sp|Q9CY58-2|PAIRB_MOUSE
242 -1.2819977 5.17366 sp|Q68FD5|CLH1_MOUSE
243 -1.2819004 5.5132895 sp|Q9JIF7|COPB_MOUSE
244 -1.2816324 3.8039558 sp|Q8CCJ3|UFL1_MOUSE
245 -1.2815514 8.87523 sp|P26443|DHE3_MOUSE
246 -1.2805405 3.4577034 sp|P26039|TLN1_MOUSE
247 -1.2801208 1.3050913 sp|Q9CPX6|ATG3_MOUSE
248 -1.2797565 2.4036503 sp|Q00PI9|HNRL2_MOUSE
249 -1.2796917 3.109283 sp|Q8BH59|CMC1_MOUSE
250 -1.2796316 1.6794106 sp|Q9WUM3|COR1B_MOUSE
251 -1.2790489 9.2091 sp|Q3UPL0-2|SC31A_MOUSE
252 -1.2786016 2.758175 sp|Q8VCA8|SCRN2_MOUSE
253 -1.2774887 3.109283 sp|Q9CQA3|SDHB_MOUSE
254 -1.27707 6.864285 sp|Q99MN9|PCCB_MOUSE
255 -1.2770615 1.3050913 sp|Q9WVJ2|PSD13_MOUSE
256 -1.2764082 8.541041 sp|Q91YQ5|RPN1_MOUSE
257 -1.2756062 3.109283 sp|Q9Z2I8-2|SUCB2_MOUSE
258 -1.2742653 1.6794106 sp|P29758|OAT_MOUSE
259 -1.2741928 2.044628 sp|P81117|NUCB2_MOUSE
260 -1.2736826 1.3050913 sp|P20357|MTAP2_MOUSE
261 -1.2730732 1.6794106 sp|Q3UM45|PP1R7_MOUSE
262 -1.2729797 1.3050913 sp|Q80UU9|PGRC2_MOUSE
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263 -1.2727833 1.3050913 sp|Q61792|LASP1_MOUSE
264 -1.2726507 5.8520784 sp|Q8BMS1|ECHA_MOUSE
265 -1.2719345 1.3050913 sp|O70503-2|DHB12_MOUSE
266 -1.2717094 2.044628 sp|O54724|CAVN1_MOUSE
267 -1.2707272 2.758175 sp|P24527|LKHA4_MOUSE
268 -1.2707233 2.4036503 sp|Q9DBC7|KAP0_MOUSE
269 -1.2700119 4.4913836 sp|P80317|TCPZ_MOUSE
270 -1.268858 6.864285 sp|P20152|VIME_MOUSE
271 -1.2685776 1.3050913 sp|P97855|G3BP1_MOUSE
272 -1.268301 3.109283 sp|Q8VCR2-2|DHB13_MOUSE
273 -1.2682877 4.4913836 sp|O08749|DLDH_MOUSE
274 -1.2681694 3.4577034 sp|Q99L88|SNTB1_MOUSE
275 -1.266922 1.6794106 sp|P61982|1433G_MOUSE
276 -1.2664375 8.20651 sp|P14148|RL7_MOUSE
277 -1.266159 2.758175 sp|Q8K0C9|GMDS_MOUSE
278 -1.2659197 1.3050913 sp|Q9D8S4|ORN_MOUSE
279 -1.2655277 3.8039558 sp|P68368|TBA4A_MOUSE
280 -1.2654095 13.544657 sp|Q61753|SERA_MOUSE
281 -1.2650509 4.14842 sp|Q99LF4|RTCB_MOUSE
282 -1.2646408 5.5132895 sp|Q91WQ3|SYYC_MOUSE
283 -1.263113 7.5362897 sp|Q922R8|PDIA6_MOUSE
284 -1.2624445 1.3050913 sp|Q921F4|HNRLL_MOUSE
285 -1.2621841 12.202081 sp|Q91VI7|RINI_MOUSE
286 -1.261591 5.8520784 sp|Q9CZD3|GARS_MOUSE
287 -1.2613306 4.8330717 sp|P11983|TCPA_MOUSE
288 -1.261198 2.758175 sp|O09167|RL21_MOUSE
289 -1.2602272 1.3050913 sp|O35129|PHB2_MOUSE
290 -1.2596807 12.202081 sp|Q8CIE6|COPA_MOUSE
291 -1.2593307 2.758175 sp|Q60932-2|VDAC1_MOUSE
292 -1.2590218 6.527502 sp|P47962|RL5_MOUSE
293 -1.2587128 2.044628 sp|Q9D7S7-2|RL22L_MOUSE
294 -1.2579155 2.758175 sp|Q8C0C7|SYFA_MOUSE
295 -1.2578335 2.044628 sp|Q8VCK7|SYCN_MOUSE
296 -1.2575798 1.3050913 sp|O70310|NMT1_MOUSE
297 -1.2570591 2.758175 sp|Q8BG32|PSD11_MOUSE
298 -1.256978 1.3050913 sp|Q99JX3-2|GORS2_MOUSE
299 -1.2556381 1.3050913 sp|Q68FL4|SAHH3_MOUSE
300 -1.2545471 4.14842 sp|Q9JMH6-2|TRXR1_MOUSE
301 -1.2544708 5.5132895 sp|Q91YI0|ARLY_MOUSE
302 -1.254446 2.044628 sp|P62264|RS14_MOUSE
303 -1.2543488 6.864285 sp|Q9CR35|CTRB1_MOUSE
304 -1.2530174 12.533645 sp|Q91ZA3|PCCA_MOUSE
305 -1.252924 2.044628 sp|Q9CXF4|TBC15_MOUSE
306 -1.2526445 1.3050913 sp|Q8K1M6-2|DNM1L_MOUSE
307 -1.2522888 2.4036503 sp|Q91W90|TXND5_MOUSE
Page 54 of 68Diabetes
SUPPLEMENTARY DATA
19
308 -1.2520561 2.044628 sp|P30999-2|CTND1_MOUSE
309 -1.2511292 1.3050913 sp|Q9QXK3-4|COPG2_MOUSE
310 -1.2510643 2.758175 sp|P14115|RL27A_MOUSE
311 -1.2509689 1.3050913 sp|Q61749-2|EI2BD_MOUSE
312 -1.2500534 7.871603 sp|Q9CPY7-2|AMPL_MOUSE
313 -1.2498074 2.044628 sp|Q9D1R9|RL34_MOUSE
314 -1.2494869 9.542674 sp|P00688|AMYP_MOUSE
315 -1.2493353 2.044628 sp|Q921F2|TADBP_MOUSE
316 -1.2482071 4.4913836 sp|P97429|ANXA4_MOUSE
317 -1.2477598 1.3050913 sp|Q3UW53|NIBAN_MOUSE
318 -1.2468872 7.5362897 sp|P14206|RSSA_MOUSE
319 -1.245183 4.8330717 sp|Q9D662|SC23B_MOUSE
320 -1.2451668 4.8330717 sp|Q8QZT1|THIL_MOUSE
321 -1.2449217 4.14842 sp|P05201|AATC_MOUSE
322 -1.2442493 2.044628 sp|O55234|PSB5_MOUSE
323 -1.2440205 1.3050913 sp|Q91W50|CSDE1_MOUSE
324 -1.2438259 1.6794106 sp|Q9D1M7|FKB11_MOUSE
325 -1.2428455 1.6794106 sp|P50544|ACADV_MOUSE
326 -1.2422352 4.14842 sp|P17563|SBP1_MOUSE
327 -1.2422047 6.527502 sp|Q9D0R2|SYTC_MOUSE
328 -1.2420607 2.4036503 sp|P40124|CAP1_MOUSE
329 -1.242033 3.4577034 sp|Q9EP69|SAC1_MOUSE
330 -1.2414513 1.3050913 sp|P68037|UB2L3_MOUSE
331 -1.2410183 2.4036503 sp|Q9JMD3|STA10_MOUSE
332 -1.2408857 13.879043 sp|P07724|ALBU_MOUSE
333 -1.2403259 1.6794106 sp|P61620|S61A1_MOUSE
334 -1.2402878 7.871603 sp|Q5BKQ4|LIPR1_MOUSE
335 -1.2398195 2.4036503 sp|Q501J6|DDX17_MOUSE
336 -1.2398071 2.4036503 sp|P43137|LIT1_MOUSE
337 -1.2398014 2.4036503 sp|Q80UM7|MOGS_MOUSE
338 -1.2397232 2.4036503 sp|Q9DBT5|AMPD2_MOUSE
339 -1.2394905 1.3050913 sp|P63085|MK01_MOUSE
340 -1.2394314 1.6794106 sp|Q61655|DD19A_MOUSE
341 -1.2394104 3.109283 sp|P07759|SPA3K_MOUSE
342 -1.2393808 2.044628 sp|P26040|EZRI_MOUSE
343 -1.2392197 1.3050913 sp|Q9D8W5|PSD12_MOUSE
344 -1.2390957 2.4036503 sp|Q9D1D4|TMEDA_MOUSE
345 -1.2390442 3.109283 sp|Q8R050-2|ERF3A_MOUSE
346 -1.2390137 8.541041 sp|Q9EQ20|MMSA_MOUSE
347 -1.2386875 2.044628 sp|P16546-2|SPTN1_MOUSE
348 -1.2385035 2.4036503 sp|P50516|VATA_MOUSE
349 -1.2384434 4.4913836 sp|Q3ULD5|MCCB_MOUSE
350 -1.2383823 1.6794106 sp|Q9Z2M7|PMM2_MOUSE
351 -1.2382393 3.109283 sp|Q9D0E1-2|HNRPM_MOUSE
352 -1.2381363 3.8039558 sp|Q9CQ52|CEL3B_MOUSE
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353 -1.2380524 5.17366 sp|Q61656|DDX5_MOUSE
354 -1.2374115 2.044628 sp|Q64737|PUR2_MOUSE
355 -1.2358093 2.4036503 sp|P62821|RAB1A_MOUSE
356 -1.2353916 1.6794106 sp|Q8BWF0|SSDH_MOUSE
357 -1.2348747 4.4913836 sp|Q922Q8|LRC59_MOUSE
358 -1.2344933 7.2005315 sp|Q9D8N0|EF1G_MOUSE
359 -1.2338982 5.5132895 sp|P32921-2|SYWC_MOUSE
360 -1.233263 4.4913836 sp|P53395|ODB2_MOUSE
361 -1.2329149 1.6794106 sp|Q62318|TIF1B_MOUSE
362 -1.2329006 1.3050913 sp|O70378|EMC8_MOUSE
363 -1.2326508 2.758175 sp|P46471|PRS7_MOUSE
364 -1.232357 6.864285 sp|P14152|MDHC_MOUSE
365 -1.2322598 2.4036503 sp|Q9WTP7|KAD3_MOUSE
366 -1.2322226 6.864285 sp|P51881|ADT2_MOUSE
367 -1.2318592 3.8039558 sp|P60229|EIF3E_MOUSE
368 -1.2318182 2.044628 sp|Q64105|SPRE_MOUSE
369 -1.2316704 2.758175 sp|Q9D6R2|IDH3A_MOUSE
370 -1.2314072 2.044628 sp|Q8CC86|PNCB_MOUSE
371 -1.2311535 3.8039558 sp|Q8BWT1|THIM_MOUSE
372 -1.230875 2.4036503 sp|Q9D1M0|SEC13_MOUSE
373 -1.2305536 2.044628 sp|P51150|RAB7A_MOUSE
374 -1.2305307 1.6794106 sp|Q00612|G6PD1_MOUSE
375 -1.2305117 4.4913836 sp|Q8BFR5|EFTU_MOUSE
376 -1.2304802 3.109283 sp|O08547|SC22B_MOUSE
377 -1.2302799 2.4036503 sp|O09131|GSTO1_MOUSE
378 -1.230217 2.4036503 sp|P07146|TRY2_MOUSE
379 -1.2294235 5.5132895 sp|P62702|RS4X_MOUSE
380 -1.2292967 8.87523 sp|Q9DBF1-2|AL7A1_MOUSE
381 -1.2286272 3.109283 sp|Q9DBE8|ALG2_MOUSE
382 -1.228198 1.3050913 sp|Q8K268|ABCF3_MOUSE
383 -1.2280216 2.4036503 sp|Q9EPU0-2|RENT1_MOUSE
384 -1.2277203 3.4577034 sp|P35980|RL18_MOUSE
385 -1.2275372 4.8330717 sp|Q9DCS3|MECR_MOUSE
386 -1.2258224 2.044628 sp|P67984|RL22_MOUSE
387 -1.2256184 2.044628 sp|P46638|RB11B_MOUSE
388 -1.2253809 1.6794106 sp|Q61699-2|HS105_MOUSE
389 -1.2244892 1.6794106 sp|Q99KJ8|DCTN2_MOUSE
390 -1.224266 3.109283 sp|Q9WUQ2|PREB_MOUSE
391 -1.2236204 1.3050913 sp|P63330|PP2AA_MOUSE
392 -1.2234249 1.6794106 sp|Q9DBE0|CSAD_MOUSE
393 -1.2232704 1.3050913 sp|O35639|ANXA3_MOUSE
394 -1.2221279 2.044628 sp|Q9DBJ1|PGAM1_MOUSE
395 -1.2198334 4.14842 sp|Q91X79|CELA1_MOUSE
396 -1.2187748 3.4577034 sp|Q9CZN7-2|GLYM_MOUSE
397 -1.2182426 2.044628 sp|P47955|RLA1_MOUSE
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398 -1.2181587 1.3050913 sp|Q8VDL4-3|ADPGK_MOUSE
399 -1.21809 1.3050913 sp|P22892|AP1G1_MOUSE
400 -1.2178001 5.5132895 sp|Q9JHI5|IVD_MOUSE
401 -1.2174044 1.3050913 sp|Q8BTY8-2|SCFD2_MOUSE
402 -1.2172241 3.109283 sp|P16460|ASSY_MOUSE
403 -1.2171345 1.6794106 sp|P62897|CYC_MOUSE
404 -1.2166939 1.6794106 sp|Q9WV32|ARC1B_MOUSE
405 -1.2147427 3.109283 sp|O08663|MAP2_MOUSE
406 -1.2141209 2.044628 sp|P60766|CDC42_MOUSE
407 -1.2137928 1.3050913 sp|Q62087|PON3_MOUSE
408 -1.2136002 5.5132895 sp|P06745|G6PI_MOUSE
409 -1.2135181 7.2005315 sp|Q8BML9|SYQ_MOUSE
410 -1.2135086 2.044628 sp|P10639|THIO_MOUSE
411 -1.2134705 2.758175 sp|O35945|AL1A7_MOUSE
412 -1.213131 7.5362897 sp|Q9D154|ILEUA_MOUSE
413 -1.2126694 7.5362897 sp|P97351|RS3A_MOUSE
414 -1.2123632 3.4577034 sp|P67778|PHB_MOUSE
415 -1.2122631 4.8330717 sp|Q8QZS1|HIBCH_MOUSE
416 -1.2121181 6.864285 sp|P14869|RLA0_MOUSE
417 -1.2116718 6.1901226 sp|Q61598|GDIB_MOUSE
418 -1.2113695 3.109283 sp|O88685|PRS6A_MOUSE
419 -1.2113047 1.3050913 sp|Q9DBG3-2|AP2B1_MOUSE
420 -1.2110729 2.4036503 sp|Q9DB29|IAH1_MOUSE
421 -1.2109756 4.8330717 sp|Q922B2|SYDC_MOUSE
422 -1.2109451 2.044628 sp|Q6PDI5-2|ECM29_MOUSE
423 -1.2104816 2.044628 sp|P62814|VATB2_MOUSE
424 -1.2103176 1.3050913 sp|Q00623|APOA1_MOUSE
425 -1.2098598 1.6794106 sp|P52480|KPYM_MOUSE
426 -1.2095823 2.044628 sp|Q60605-2|MYL6_MOUSE
427 -1.2094078 4.4913836 sp|Q68FL6|SYMC_MOUSE
428 -1.2086239 1.3050913 sp|P17225|PTBP1_MOUSE
429 -1.2081375 3.109283 sp|P59325|IF5_MOUSE
430 -1.2079468 2.758175 sp|Q61425|HCDH_MOUSE
431 -1.2077026 4.14842 sp|P63101|1433Z_MOUSE
432 -1.2072868 2.044628 sp|P16254|SRP14_MOUSE
433 -1.2065659 2.4036503 sp|Q9DBL1|ACDSB_MOUSE
434 -1.20607 2.4036503 sp|Q60928|GGT1_MOUSE
435 -1.2052937 5.17366 sp|Q99LB7|SARDH_MOUSE
436 -1.2052326 1.6794106 sp|P22599|A1AT2_MOUSE
437 -1.2049294 3.109283 sp|P62830|RL23_MOUSE
438 -1.2048836 2.044628 sp|Q9DB20|ATPO_MOUSE
439 -1.20401 2.044628 sp|Q9QUR6|PPCE_MOUSE
440 -1.2036858 2.758175 sp|P15947|KLK1_MOUSE
441 -1.2035866 3.4577034 sp|P19001|K1C19_MOUSE
442 -1.2031517 1.3050913 sp|Q6PB66|LPPRC_MOUSE
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443 -1.202982 1.3050913 sp|P50096|IMDH1_MOUSE
444 -1.2026825 3.8039558 sp|Q9CYR6|AGM1_MOUSE
445 -1.2026491 2.044628 sp|Q9CZ30|OLA1_MOUSE
446 -1.2025928 2.4036503 sp|P62245|RS15A_MOUSE
447 -1.2021599 2.758175 sp|Q8K0C5|ZG16_MOUSE
448 -1.2017212 2.758175 sp|Q91X83|METK1_MOUSE
449 -1.2005901 1.6794106 sp|Q922W5|P5CR1_MOUSE
450 -1.2005043 7.2005315 sp|P47856-2|GFPT1_MOUSE
451 -1.200057 2.4036503 sp|Q9DCL9|PUR6_MOUSE
452 -1.1999035 12.202081 sp|P05784|K1C18_MOUSE
453 -1.1997299 3.8039558 sp|Q99JR1|SFXN1_MOUSE
454 -1.199727 3.8039558 sp|P24549|AL1A1_MOUSE
455 -1.1993027 8.87523 sp|P14824|ANXA6_MOUSE
456 -1.199131 7.871603 sp|Q8BP47|SYNC_MOUSE
457 -1.1989794 3.8039558 sp|Q9D1A2|CNDP2_MOUSE
458 -1.1985054 1.6794106 sp|Q9CQM9|GLRX3_MOUSE
459 -1.1983871 1.6794106 sp|Q9JMA1|UBP14_MOUSE
460 -1.1983643 2.044628 sp|P47740|AL3A2_MOUSE
461 -1.1980343 2.4036503 sp|P60867|RS20_MOUSE
462 -1.1972475 4.14842 sp|P97807-2|FUMH_MOUSE
463 -1.1962757 1.3050913 sp|P62874|GBB1_MOUSE
464 -1.1960812 2.4036503 sp|P00687|AMY1_MOUSE
465 -1.1949425 2.758175 sp|O54734|OST48_MOUSE
466 -1.1939955 2.4036503 sp|P54775|PRS6B_MOUSE
467 -1.1938419 5.8520784 sp|O88844|IDHC_MOUSE
468 -1.1938324 5.5132895 sp|Q64442|DHSO_MOUSE
469 -1.1936865 1.3050913 sp|A3KMP2|TTC38_MOUSE
470 -1.1935654 1.3050913 sp|P62855|RS26_MOUSE
471 -1.1931896 6.1901226 sp|P56480|ATPB_MOUSE
472 -1.1927719 9.2091 sp|Q9D0I9|SYRC_MOUSE
473 -1.1926117 3.4577034 sp|Q9JII6|AK1A1_MOUSE
474 -1.19244 1.6794106 sp|P97364|SPS2_MOUSE
475 -1.1923447 1.3050913 sp|O88342|WDR1_MOUSE
476 -1.1920319 1.6794106 sp|P70349|HINT1_MOUSE
477 -1.1919155 1.6794106 sp|Q9QXB9|DRG2_MOUSE
478 -1.191803 2.4036503 sp|P12787|COX5A_MOUSE
479 -1.1913805 5.17366 sp|P57776-2|EF1D_MOUSE
480 -1.1909008 2.758175 sp|Q3UGC7|EI3JA_MOUSE
481 -1.1903687 2.4036503 sp|Q9DCD0|6PGD_MOUSE
482 -1.1902828 1.3050913 sp|Q9ESP1|SDF2L_MOUSE
483 -1.1898289 1.6794106 sp|Q9DCC4|P5CR3_MOUSE
484 -1.189579 1.6794106 sp|Q505F5|LRC47_MOUSE
485 -1.1889296 1.3050913 sp|P31786|ACBP_MOUSE
486 -1.1883411 4.14842 sp|P45376|ALDR_MOUSE
487 -1.1882343 4.8330717 sp|Q6ZWV3|RL10_MOUSE
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488 -1.1880875 2.4036503 sp|Q9CQ60|6PGL_MOUSE
489 -1.1876583 1.6794106 sp|Q9JHH9|COPZ2_MOUSE
490 -1.1874218 1.3050913 sp|P70404|IDHG1_MOUSE
491 -1.1870861 4.14842 sp|Q9WUA2|SYFB_MOUSE
492 -1.1869183 1.3050913 sp|P70372|ELAV1_MOUSE
493 -1.1869135 1.6794106 sp|Q99KV1|DJB11_MOUSE
494 -1.1862221 1.3050913 sp|P97315|CSRP1_MOUSE
495 -1.1851444 3.4577034 sp|Q8BRF7|SCFD1_MOUSE
496 -1.1847076 1.6794106 sp|P10107|ANXA1_MOUSE
497 -1.1841087 4.8330717 sp|Q8VCN5|CGL_MOUSE
498 -1.1839962 3.109283 sp|Q91Z53|GRHPR_MOUSE
499 -1.1836319 1.3050913 sp|Q8BJY1|PSMD5_MOUSE
500 -1.1835632 3.8039558 sp|P35979|RL12_MOUSE
501 -1.1831312 6.1901226 sp|P17751|TPIS_MOUSE
502 -1.1825371 1.6794106 sp|Q9EPE9|AT131_MOUSE
503 -1.1824512 5.8520784 sp|P05208|CEL2A_MOUSE
504 -1.182064 1.3050913 sp|Q99LD9|EI2BB_MOUSE
505 -1.1816406 1.3050913 sp|P63073|IF4E_MOUSE
506 -1.1809025 3.109283 sp|P41216|ACSL1_MOUSE
507 -1.1803513 1.3050913 sp|Q9CQC6|BZW1_MOUSE
508 -1.180027 2.044628 sp|Q02248|CTNB1_MOUSE
509 -1.1800194 4.8330717 sp|Q9JLJ2|AL9A1_MOUSE
510 -1.1799641 3.109283 sp|P47758|SRPRB_MOUSE
511 -1.1795483 2.4036503 sp|Q99KK7|DPP3_MOUSE
512 -1.1788673 6.864285 sp|P47738|ALDH2_MOUSE
513 -1.1785793 1.6794106 sp|P63005-2|LIS1_MOUSE
514 -1.1780281 1.6794106 sp|Q99KR7|PPIF_MOUSE
515 -1.1776447 3.4577034 sp|Q3TW96|UAP1L_MOUSE
516 -1.1773138 2.044628 sp|Q99020|ROAA_MOUSE
517 -1.1772804 2.758175 sp|Q3ULJ0-2|GPD1L_MOUSE
518 -1.1771526 5.8520784 sp|P09411|PGK1_MOUSE
519 -1.176693 1.3050913 sp|Q9WUP7-2|UCHL5_MOUSE
520 -1.1761904 5.8520784 sp|P06151|LDHA_MOUSE
521 -1.1761398 4.4913836 sp|P62281|RS11_MOUSE
522 -1.1751757 3.8039558 sp|Q99L04|DHRS1_MOUSE
523 -1.1737366 2.4036503 sp|Q99PT1|GDIR1_MOUSE
524 -1.1736565 2.758175 sp|Q3UPH1|PRRC1_MOUSE
525 -1.1735573 6.1901226 sp|P05202|AATM_MOUSE
526 -1.1734276 1.6794106 sp|P61089|UBE2N_MOUSE
527 -1.1726398 2.4036503 sp|Q9QUM9|PSA6_MOUSE
528 -1.1719694 3.109283 sp|P60843|IF4A1_MOUSE
529 -1.1717148 1.3050913 sp|Q60692|PSB6_MOUSE
530 -1.1711302 3.109283 sp|P35505|FAAA_MOUSE
531 -1.1709566 5.8520784 sp|O88986|KBL_MOUSE
532 -1.170826 3.4577034 sp|P14576|SRP54_MOUSE
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533 -1.1706753 2.4036503 sp|Q9CQR2|RS21_MOUSE
534 -1.17066 6.1901226 sp|Q6ZWN5|RS9_MOUSE
535 -1.1703405 11.539065 sp|Q61024|ASNS_MOUSE
536 -1.1703348 2.044628 sp|Q8BWY3|ERF1_MOUSE
537 -1.1702461 5.5132895 sp|P51410|RL9_MOUSE
538 -1.16922 1.6794106 sp|Q9Z1N5|DX39B_MOUSE
539 -1.1691589 1.6794106 sp|P62751|RL23A_MOUSE
540 -1.166542 1.3050913 sp|P35293|RAB18_MOUSE
541 -1.1659575 2.044628 sp|Q8K183|PDXK_MOUSE
542 -1.1644859 1.3050913 sp|B2RSH2|GNAI1_MOUSE
543 -1.1639977 2.044628 sp|Q99L47|F10A1_MOUSE
544 -1.1637392 2.758175 sp|Q9Z204-2|HNRPC_MOUSE
545 -1.1633167 3.4577034 sp|P35486|ODPA_MOUSE
546 -1.16325 9.2091 sp|P17182|ENOA_MOUSE
547 -1.1630039 2.4036503 sp|P68254-2|1433T_MOUSE
548 -1.1629868 1.6794106 sp|P42669|PURA_MOUSE
549 -1.1629524 1.3050913 sp|Q99JT9|MTND_MOUSE
550 -1.1629381 1.6794106 sp|Q8BFY9-2|TNPO1_MOUSE
551 -1.1622543 2.044628 sp|Q8BVI4|DHPR_MOUSE
552 -1.1620283 1.3050913 sp|Q8R059|GALE_MOUSE
553 -1.1615868 1.3050913 sp|P61924|COPZ1_MOUSE
554 -1.160984 4.14842 sp|Q9Z0N1|IF2G_MOUSE
555 -1.1597481 2.4036503 sp|Q9QZD9|EIF3I_MOUSE
556 -1.1596756 2.044628 sp|Q62465|VAT1_MOUSE
557 -1.1595402 2.044628 sp|Q99JY0|ECHB_MOUSE
558 -1.1595078 1.3050913 sp|Q9QYJ0|DNJA2_MOUSE
559 -1.1592178 1.3050913 sp|B2RQC6-2|PYR1_MOUSE
560 -1.1588058 3.8039558 sp|P62082|RS7_MOUSE
561 -1.1584663 3.109283 sp|Q91YT0|NDUV1_MOUSE
562 -1.1580219 2.758175 sp|Q9CZU6|CISY_MOUSE
563 -1.1574211 2.758175 sp|Q8VEM8|MPCP_MOUSE
564 -1.1571522 2.044628 sp|Q9CQ62|DECR_MOUSE
565 -1.1565971 1.6794106 sp|Q9Z2U0|PSA7_MOUSE
566 -1.156208 1.3050913 sp|Q63932|MP2K2_MOUSE
567 -1.1557693 2.4036503 sp|P07356|ANXA2_MOUSE
568 -1.1547451 4.4913836 sp|Q9CZX8|RS19_MOUSE
569 -1.1545506 1.3050913 sp|Q9Z0L8-2|GGH_MOUSE
570 -1.154439 8.87523 sp|Q9D964|GATM_MOUSE
571 -1.1544151 1.3050913 sp|Q9CPQ8|ATP5L_MOUSE
572 -1.1543827 2.4036503 sp|Q9D2G2-2|ODO2_MOUSE
573 -1.1542625 2.758175 sp|Q9CPV4|GLOD4_MOUSE
574 -1.1527195 2.044628 sp|P49312-2|ROA1_MOUSE
575 -1.1526899 1.6794106 sp|Q9WUM4|COR1C_MOUSE
576 -1.1514435 1.3050913 sp|Q9D358-2|PPAC_MOUSE
577 -1.1514091 2.044628 sp|P13707|GPDA_MOUSE
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578 -1.1512756 1.6794106 sp|Q99L13|3HIDH_MOUSE
579 -1.1506748 1.3050913 sp|P54822|PUR8_MOUSE
580 -1.1505117 2.044628 sp|Q91V41|RAB14_MOUSE
581 -1.1504059 4.14842 sp|O70251|EF1B_MOUSE
582 -1.1497898 4.4913836 sp|P62270|RS18_MOUSE
583 -1.1495504 3.109283 sp|Q9WUK2-2|IF4H_MOUSE
584 -1.1489086 1.6794106 sp|Q9EQP2|EHD4_MOUSE
585 -1.1481438 2.758175 sp|Q8BTZ7|GMPPB_MOUSE
586 -1.1479921 1.3050913 sp|P12367|KAP2_MOUSE
587 -1.1472387 1.3050913 sp|Q9Z1Q5|CLIC1_MOUSE
588 -1.146718 1.6794106 sp|P35276|RAB3D_MOUSE
589 -1.146718 4.14842 sp|Q9R0P3|ESTD_MOUSE
590 -1.1466923 1.6794106 sp|Q62186|SSRD_MOUSE
591 -1.145338 2.758175 sp|Q8CG76|ARK72_MOUSE
592 -1.1451931 7.5362897 sp|P10126|EF1A1_MOUSE
593 -1.1447754 1.6794106 sp|O08605|MKNK1_MOUSE
594 -1.1446972 1.3050913 sp|Q8K3J1|NDUS8_MOUSE
595 -1.1445351 6.527502 sp|P54071|IDHP_MOUSE
596 -1.1444817 1.6794106 sp|Q9DB05|SNAA_MOUSE
597 -1.1439724 5.8520784 sp|Q71RI9-2|KAT3_MOUSE
598 -1.1431608 3.4577034 sp|O89079|COPE_MOUSE
599 -1.142704 1.6794106 sp|Q60759|GCDH_MOUSE
600 -1.1425323 1.6794106 sp|P03336|GAG_MLVAV
601 -1.1424065 3.109283 sp|P63325|RS10_MOUSE
602 -1.1409607 3.109283 sp|P63242|IF5A1_MOUSE
603 -1.1404762 5.8520784 sp|P16858|G3P_MOUSE
604 -1.1403866 13.879043 sp|P11679|K2C8_MOUSE
605 -1.1400976 1.3050913 sp|Q3THK7|GUAA_MOUSE
606 -1.1398773 4.14842 sp|P62259|1433E_MOUSE
607 -1.1394539 3.8039558 sp|P55264-2|ADK_MOUSE
608 -1.1384506 2.758175 sp|Q07417|ACADS_MOUSE
609 -1.1378603 3.4577034 sp|P97461|RS5_MOUSE
610 -1.1370087 1.3050913 sp|Q9JHR7|IDE_MOUSE
611 -1.1349316 1.3050913 sp|Q8VCW8|ACSF2_MOUSE
612 -1.1329117 1.6794106 sp|O55022|PGRC1_MOUSE
613 -1.1324539 9.875973 sp|Q62167|DDX3X_MOUSE
614 -1.1315155 2.4036503 sp|P60335|PCBP1_MOUSE
615 -1.1312065 1.6794106 sp|P16045|LEG1_MOUSE
616 -1.1303768 5.5132895 sp|P05064|ALDOA_MOUSE
617 -1.1301899 2.758175 sp|P52825|CPT2_MOUSE
618 -1.1299324 2.044628 sp|Q8QZY1|EIF3L_MOUSE
619 -1.1297264 1.6794106 sp|Q9DBZ5|EIF3K_MOUSE
620 -1.1294155 2.044628 sp|P10518|HEM2_MOUSE
621 -1.1289959 4.14842 sp|Q9Z2W0|DNPEP_MOUSE
622 -1.1285181 1.6794106 sp|P62880|GBB2_MOUSE
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623 -1.1283092 2.4036503 sp|Q8BMF4|ODP2_MOUSE
624 -1.1281643 1.6794106 sp|P99027|RLA2_MOUSE
625 -1.1278677 5.5132895 sp|Q99K85|SERC_MOUSE
626 -1.1272163 1.6794106 sp|Q64471|GSTT1_MOUSE
627 -1.1268978 1.3050913 sp|Q61510|TRI25_MOUSE
628 -1.1265507 2.4036503 sp|Q9D172|GAL3A_MOUSE
629 -1.1265383 3.109283 sp|Q04447|KCRB_MOUSE
630 -1.1263762 3.109283 sp|P80315|TCPD_MOUSE
631 -1.126358 3.109283 sp|O35969-2|GAMT_MOUSE
632 -1.1262836 2.044628 sp|Q9R1P4|PSA1_MOUSE
633 -1.1249123 8.20651 sp|P50247|SAHH_MOUSE
634 -1.1245079 4.4913836 sp|P24369|PPIB_MOUSE
635 -1.1243048 3.109283 sp|Q9R0P5|DEST_MOUSE
636 -1.1225996 1.6794106 sp|Q62393-2|TPD52_MOUSE
637 -1.1221457 1.6794106 sp|Q8BP48|MAP11_MOUSE
638 -1.1221275 3.4577034 sp|O08709|PRDX6_MOUSE
639 -1.1220894 2.044628 sp|Q9JJI8|RL38_MOUSE
640 -1.1220264 3.8039558 sp|O35855|BCAT2_MOUSE
641 -1.1214447 1.6794106 sp|Q99KC8|VMA5A_MOUSE
642 -1.120224 4.4913836 sp|Q9D051|ODPB_MOUSE
643 -1.1194305 1.3050913 sp|P47791-2|GSHR_MOUSE
644 -1.1193085 1.6794106 sp|Q9JLZ3|AUHM_MOUSE
645 -1.1181297 1.3050913 sp|Q8QZR5|ALAT1_MOUSE
646 -1.1180878 1.3050913 sp|Q9DCH4|EIF3F_MOUSE
647 -1.1177883 2.044628 sp|P49722|PSA2_MOUSE
648 -1.1174593 2.044628 sp|Q9CQ65|MTAP_MOUSE
649 -1.1165123 1.3050913 sp|Q9QUI0|RHOA_MOUSE
650 -1.1159191 2.758175 sp|Q9WTP6-2|KAD2_MOUSE
651 -1.115036 2.758175 sp|Q9DCS2|MTL26_MOUSE
652 -1.1111603 2.044628 sp|Q9DCN2-2|NB5R3_MOUSE
653 -1.110589 1.3050913 sp|Q91V76|CK054_MOUSE
654 -1.1104412 2.044628 sp|Q9Z0S1|BPNT1_MOUSE
655 -1.1097298 2.044628 sp|P57759|ERP29_MOUSE
656 -1.1096573 1.6794106 sp|Q8CHP8|PGP_MOUSE
657 -1.1084394 1.6794106 sp|Q9CPP6|NDUA5_MOUSE
658 -1.1083565 2.044628 sp|Q6P3A8-2|ODBB_MOUSE
659 -1.1078281 2.4036503 sp|P23591|FCL_MOUSE
660 -1.1077929 2.044628 sp|Q99JW2|ACY1_MOUSE
661 -1.1074533 2.4036503 sp|Q8CDN6|TXNL1_MOUSE
662 -1.1061687 1.3050913 sp|P62334|PRS10_MOUSE
663 -1.1043339 2.4036503 sp|O08756|HCD2_MOUSE
664 -1.1033707 5.8520784 sp|Q99LC5|ETFA_MOUSE
665 -1.1031055 1.6794106 sp|P70296|PEBP1_MOUSE
666 -1.1027069 1.6794106 sp|Q9CQC2|COL_MOUSE
667 -1.1026287 1.3050913 sp|Q9CYN2|SPCS2_MOUSE
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668 -1.1007032 1.3050913 sp|P61082|UBC12_MOUSE
669 -1.0978203 5.5132895 sp|P48758|CBR1_MOUSE
670 -1.0973434 2.758175 sp|Q99J77|SIAS_MOUSE
671 -1.0968475 3.8039558 sp|P62301|RS13_MOUSE
672 -1.0965519 3.8039558 sp|Q64674|SPEE_MOUSE
673 -1.0955677 1.6794106 sp|Q05816|FABP5_MOUSE
674 -1.0951557 2.758175 sp|Q9D7B6|ACAD8_MOUSE
675 -1.09441 2.758175 sp|P35700|PRDX1_MOUSE
676 -1.0940285 2.044628 sp|P08228|SODC_MOUSE
677 -1.0935612 1.3050913 sp|Q99JX4|EIF3M_MOUSE
678 -1.0930023 1.6794106 sp|Q922H4|GMPPA_MOUSE
679 -1.0929871 1.3050913 sp|Q60668-2|HNRPD_MOUSE
680 -1.0912857 3.8039558 sp|P63276|RS17_MOUSE
681 -1.0904655 3.109283 sp|P28474|ADHX_MOUSE
682 -1.0902042 1.6794106 sp|P62835|RAP1A_MOUSE
683 -1.0896196 1.3050913 sp|P62849-2|RS24_MOUSE
684 -1.0894089 1.3050913 sp|P56391|CX6B1_MOUSE
685 -1.0887585 1.3050913 sp|Q9R062|GLYG_MOUSE
686 -1.0879536 2.044628 sp|Q9JK38|GNA1_MOUSE
687 -1.0871983 4.4913836 sp|P18760|COF1_MOUSE
688 -1.086916 1.6794106 sp|O70400|PDLI1_MOUSE
689 -1.0858173 2.758175 sp|Q61171|PRDX2_MOUSE
690 -1.0835028 1.3050913 sp|Q61490|CD166_MOUSE
691 -1.0825024 1.3050913 sp|O08691|ARGI2_MOUSE
692 -1.0819969 1.3050913 sp|P52760|RIDA_MOUSE
693 -1.0818291 3.109283 sp|Q60930|VDAC2_MOUSE
694 -1.0809746 4.8330717 sp|Q9DCW4|ETFB_MOUSE
695 -1.0768194 2.044628 sp|Q8VC28|AK1CD_MOUSE
696 -1.0767021 1.3050913 sp|P18242|CATD_MOUSE
697 -1.0762653 8.87523 sp|P08249|MDHM_MOUSE
698 -1.0760937 7.5362897 sp|P68040|RACK1_MOUSE
699 -1.0760603 2.044628 sp|P53994|RAB2A_MOUSE
700 -1.075716 2.044628 sp|Q9CPU0|LGUL_MOUSE
701 -1.0754766 1.6794106 sp|Q91ZJ5-2|UGPA_MOUSE
702 -1.0735226 1.6794106 sp|P62827|RAN_MOUSE
703 -1.0692596 1.6794106 sp|Q61990-2|PCBP2_MOUSE
704 -1.0691986 1.3050913 sp|Q9Z2U1|PSA5_MOUSE
705 -1.0689297 3.109283 sp|Q9D819|IPYR_MOUSE
706 -1.0689259 2.044628 sp|O35215|DOPD_MOUSE
707 -1.0682068 1.3050913 sp|P30115|GSTA3_MOUSE
708 -1.0657978 2.044628 sp|Q3SYP2|CTRC_MOUSE
709 -1.0642433 2.758175 sp|P52196|THTR_MOUSE
710 -1.0620289 2.758175 sp|Q99L20|GSTT3_MOUSE
711 -1.0597897 2.044628 sp|P62196|PRS8_MOUSE
712 -1.0595093 4.8330717 sp|Q8BH95|ECHM_MOUSE
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713 -1.0560722 2.758175 sp|Q9WVA4|TAGL2_MOUSE
714 -1.0556202 4.14842 sp|P63323|RS12_MOUSE
715 -1.0548668 4.8330717 sp|P10649|GSTM1_MOUSE
716 -1.0540771 10.209015 sp|P62908|RS3_MOUSE
717 -1.0534363 2.758175 sp|P68369|TBA1A_MOUSE
718 -1.0515995 1.6794106 sp|Q91V64|ISOC1_MOUSE
719 -1.0514774 2.044628 sp|Q8R164|BPHL_MOUSE
720 -1.0509663 2.4036503 sp|P61458|PHS_MOUSE
721 -1.0502453 1.6794106 sp|P85094|ISC2A_MOUSE
722 -1.0480881 1.6794106 sp|P59999|ARPC4_MOUSE
723 -1.0436516 1.3050913 sp|Q9CQE8|RTRAF_MOUSE
724 -1.0411072 1.3050913 sp|Q9D6J6|NDUV2_MOUSE
725 -1.040082 3.109283 sp|Q9DBP5|KCY_MOUSE
726 -1.0398941 1.3050913 sp|P62852|RS25_MOUSE
727 -1.038868 2.758175 sp|P42125|ECI1_MOUSE
728 -1.0380573 3.109283 sp|P53026|RL10A_MOUSE
729 -1.0365582 3.8039558 sp|P48036|ANXA5_MOUSE
730 -1.0364647 1.3050913 sp|O54984|ASNA_MOUSE
731 -1.0322914 1.3050913 sp|Q91VR2|ATPG_MOUSE
732 -1.0300941 1.3050913 sp|P56959|FUS_MOUSE
733 -1.0268536 1.3050913 sp|P38060|HMGCL_MOUSE
734 -1.0248852 4.4913836 sp|P17742|PPIA_MOUSE
735 -1.024353 2.044628 sp|O55142|RL35A_MOUSE
736 -1.0221062 1.3634305 sp|P30416|FKBP4_MOUSE
737 -1.0180988 1.6794106 sp|P63028|TCTP_MOUSE
738 -1.0178442 3.109283 sp|P62962|PROF1_MOUSE
739 -1.0130997 2.4036503 sp|Q9CXW4|RL11_MOUSE
740 -1.0070839 4.4913836 sp|O88569-2|ROA2_MOUSE
741 -1.0063515 1.6794106 sp|P62858|RS28_MOUSE
742 -1.0013771 5.17366 sp|P19157|GSTP1_MOUSE
743 -0.9943714 2.758175 sp|P99029-2|PRDX5_MOUSE
744 -0.9920082 3.4577034 sp|Q9QXF8|GNMT_MOUSE
745 -0.9902792 1.3050913 sp|O35658|C1QBP_MOUSE
746 -0.98579407 3.109283 sp|P14131|RS16_MOUSE
747 -0.9848137 1.3050913 sp|Q07076|ANXA7_MOUSE
748 -0.98314095 2.758175 sp|P62889|RL30_MOUSE
749 -0.97930527 2.044628 sp|Q9CQM5|TXD17_MOUSE
750 -0.9738865 3.8039558 sp|P15626|GSTM2_MOUSE
751 -0.96040344 1.3050913 sp|P00329|ADH1_MOUSE
752 -0.95006275 1.6794106 sp|Q91X72|HEMO_MOUSE
753 -0.94696236 1.3050913 sp|Q9WVL0|MAAI_MOUSE
754 -0.9423332 1.6794106 sp|P02535-2|K1C10_MOUSE
755 -0.9328289 1.3050913 sp|Q9R1P1|PSB3_MOUSE
756 -0.9205513 1.6794106 sp|Q01768|NDKB_MOUSE
757 -0.918993 1.3050913 sp|P16125|LDHB_MOUSE
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758 -0.91344833 3.109283 sp|P01942|HBA_MOUSE
759 -0.8999491 1.3050913 sp|Q64010-2|CRK_MOUSE
760 -0.8672409 1.6794106 sp|P04117|FABP4_MOUSE
761 -0.85577774 1.3050913 sp|Q9JKB1|UCHL3_MOUSE
762 -0.80261326 1.3050913 sp|P15532|NDKA_MOUSE
763 -0.76784515 2.4036503 sp|P02088|HBB1_MOUSE
764 -0.6644497 1.3050913 sp|P02798|MT2_MOUSE
765 -0.57154083 1.3050913 sp|P02802|MT1_MOUSE
Supplementary Table 2. Citrullinated proteins in pancreas of 
BB-Cl-amidine treated versus DMSO treated NOD mice not 
significantly altered by the treatment
** P≥0.05 (Log10p-value = 1.122)
 Log2Ratio Log10p-value (**) Accession
1 -1.7894802 0.49851555 sp|P23953|EST1C_MOUSE
2 -1.6683903 0.91601306 sp|O08786|CCKAR_MOUSE
3 -1.6681643 0.49851555 sp|P53996|CNBP_MOUSE
4 -1.6120167 0.91601306 sp|P83882|RL36A_MOUSE
5 -1.580823 0.91601306 sp|Q9JKB3-2|YBOX3_MOUSE
6 -1.5767965 0.49851555 sp|P48774|GSTM5_MOUSE
7 -1.5470638 0.49851555 sp|O35643|AP1B1_MOUSE
8 -1.5351009 0.91601306 sp|Q8CHW4|EI2BE_MOUSE
9 -1.5293589 0.91601306 sp|Q9CQJ6|DENR_MOUSE
10 -1.5259628 0.91601306 sp|P70441|NHRF1_MOUSE
11 -1.519249 0.91601306 sp|P63328-2|PP2BA_MOUSE
12 -1.4998703 0.91601306 sp|Q6GQT9|NOMO1_MOUSE
13 -1.4967995 0.91601306 sp|Q99LE6|ABCF2_MOUSE
14 -1.4886131 0.91601306 sp|O54692|ZW10_MOUSE
15 -1.4832001 0.91601306 sp|Q9ERK4|XPO2_MOUSE
16 -1.4829292 0.91601306 sp|Q791V5|MTCH2_MOUSE
17 -1.481122 0.49851555 sp|Q8BFZ3|ACTBL_MOUSE
18 -1.4794674 0.91601306 sp|Q9D281|NXP20_MOUSE
19 -1.4741497 0.91601306 sp|Q11136|PEPD_MOUSE
20 -1.4740906 0.91601306 sp|Q60598|SRC8_MOUSE
21 -1.472992 0.91601306 sp|Q91XE8|TM205_MOUSE
22 -1.4608564 0.91601306 sp|P14685|PSMD3_MOUSE
23 -1.4468403 0.91601306 sp|A2ALW5|DJC25_MOUSE
24 -1.4434948 0.91601306 sp|Q6PB93-2|GALT2_MOUSE
25 -1.4420519 0.49851555 sp|P48722-2|HS74L_MOUSE
26 -1.4326811 0.91601306 sp|O88543|CSN3_MOUSE
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27 -1.4253664 0.91601306 sp|Q9QXX4|CMC2_MOUSE
28 -1.4231462 0.91601306 sp|Q9Z1W9|STK39_MOUSE
29 -1.4202251 0.49851555 sp|Q9D2M8-2|UB2V2_MOUSE
30 -1.414794 0.91601306 sp|P35235-2|PTN11_MOUSE
31 -1.4048777 0.91601306 sp|P17918|PCNA_MOUSE
32 -1.4022331 0.49851555 sp|P84084|ARF5_MOUSE
33 -1.3996744 0.91601306 sp|Q62448-2|IF4G2_MOUSE
34 -1.3991852 0.49851555 sp|P61205|ARF3_MOUSE
35 -1.3975315 0.49851555 sp|Q8R5C5|ACTY_MOUSE
36 -1.3934231 0.91601306 sp|P08752|GNAI2_MOUSE
37 -1.3886375 0.49851555 sp|P63094-2|GNAS2_MOUSE
38 -1.3862152 0.91601306 sp|Q9D379|HYEP_MOUSE
39 -1.3848953 0.91601306 sp|Q8BMP6|GCP60_MOUSE
40 -1.3750544 0.91601306 sp|P70195|PSB7_MOUSE
41 -1.3742962 0.91601306 sp|P47964|RL36_MOUSE
42 -1.3739471 0.91601306 sp|Q9CR62|M2OM_MOUSE
43 -1.3707561 0.49851555 sp|P21107|TPM3_MOUSE
44 -1.368391 0.91601306 sp|P32067|LA_MOUSE
45 -1.3655033 0.91601306 sp|Q9R099|TBL2_MOUSE
46 -1.3651772 0.91601306 sp|Q8BW75|AOFB_MOUSE
47 -1.3639383 0.91601306 sp|P36536|SAR1A_MOUSE
48 -1.3636379 0.91601306 sp|Q9DC51|GNAI3_MOUSE
49 -1.3608398 0.91601306 sp|Q62446|FKBP3_MOUSE
50 -1.3594933 0.91601306 sp|Q9D8V0-3|HM13_MOUSE
51 -1.3579845 0.91601306 sp|Q9D2R4|TMD11_MOUSE
52 -1.3569355 0.91601306 sp|Q8R1F6-2|HID1_MOUSE
53 -1.3559589 0.91601306 sp|O08788-2|DCTN1_MOUSE
54 -1.3549404 0.91601306 sp|Q9CR68|UCRI_MOUSE
55 -1.3546295 0.91601306 sp|Q8BVE3|VATH_MOUSE
56 -1.3509512 0.91601306 sp|Q9CWK8|SNX2_MOUSE
57 -1.3440714 0.91601306 sp|Q9D5V6|SYAP1_MOUSE
58 -1.3432989 0.49851555 sp|P53996-2|CNBP_MOUSE
59 -1.3417873 0.91601306 sp|Q9JIZ0|CMLO1_MOUSE
60 -1.3416767 0.49851555 sp|P26041|MOES_MOUSE
61 -1.3410187 0.91601306 sp|Q8BX90|FND3A_MOUSE
62 -1.3388853 0.91601306 sp|P47226-2|TES_MOUSE
63 -1.3375111 0.91601306 sp|Q8BLF1|NCEH1_MOUSE
64 -1.3332996 0.91601306 sp|Q9CQF9|PCYOX_MOUSE
65 -1.3274622 0.91601306 sp|Q920E5|FPPS_MOUSE
66 -1.3102036 0.91601306 sp|P19536|COX5B_MOUSE
67 -1.3058357 0.91601306 sp|P60670-2|NPL4_MOUSE
68 -1.3058205 0.91601306 sp|P10853|H2B1F_MOUSE
69 -1.3057585 0.91601306 sp|Q99K28-2|ARFG2_MOUSE
70 -1.3037853 0.91601306 sp|O88544|CSN4_MOUSE
71 -1.3005562 0.91601306 sp|Q9JII5-2|DAZP1_MOUSE
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72 -1.2993164 0.91601306 sp|Q6ZPJ3|UBE2O_MOUSE
73 -1.2982349 0.91601306 sp|O70435|PSA3_MOUSE
74 -1.2982273 0.91601306 sp|P28656|NP1L1_MOUSE
75 -1.2957315 0.91601306 sp|Q8K4F5|ABHDB_MOUSE
76 -1.2951851 0.49851555 sp|Q8BG05-2|ROA3_MOUSE
77 -1.2950277 0.91601306 sp|P61079|UB2D3_MOUSE
78 -1.2935734 0.49851555 sp|Q9DCG6|PBLD1_MOUSE
79 -1.2907848 0.91601306 sp|P97328|KHK_MOUSE
80 -1.2887697 0.91601306 sp|Q8BWG8-2|ARRB1_MOUSE
81 -1.2876129 0.91601306 sp|Q60872|IF1A_MOUSE
82 -1.2811394 0.49851555 sp|Q6IFX2|K1C42_MOUSE
83 -1.2802505 0.91601306 sp|Q9CXT8|MPPB_MOUSE
84 -1.2752724 0.91601306 sp|Q8VDM6-2|HNRL1_MOUSE
85 -1.2748566 0.91601306 sp|Q4VAA2-2|CDV3_MOUSE
86 -1.2747765 0.91601306 sp|Q9WVP1-2|AP1M2_MOUSE
87 -1.2743025 0.91601306 sp|P62737|ACTA_MOUSE
88 -1.273632 0.91601306 sp|P61161|ARP2_MOUSE
89 -1.272152 0.91601306 sp|Q922Q4|P5CR2_MOUSE
90 -1.2720823 0.91601306 sp|Q8R1Q8|DC1L1_MOUSE
91 -1.2703238 0.91601306 sp|Q9JJK5|HERP1_MOUSE
92 -1.2654572 0.91601306 sp|Q9CZY3|UB2V1_MOUSE
93 -1.2645807 0.91601306 sp|Q6ZPE2-2|MTMR5_MOUSE
94 -1.2635231 0.91601306 sp|Q60710-2|SAMH1_MOUSE
95 -1.262888 0.91601306 sp|P50431|GLYC_MOUSE
96 -1.2597857 0.91601306 sp|Q3TZM9-2|ALG11_MOUSE
97 -1.2529278 0.91601306 sp|Q9CXN7|PBLD2_MOUSE
98 -1.2518997 0.49851555 sp|P62137|PP1A_MOUSE
99 -1.2499361 0.91601306 sp|Q8VI75|IPO4_MOUSE
100 -1.2495613 0.91601306 sp|Q99LB2|DHRS4_MOUSE
101 -1.2485752 0.91601306 sp|P22907-2|HEM3_MOUSE
102 -1.2483006 0.91601306 sp|P56395|CYB5_MOUSE
103 -1.2480507 0.49851555 sp|P21107-2|TPM3_MOUSE
104 -1.2457695 0.91601306 sp|Q9DCJ5|NDUA8_MOUSE
105 -1.243103 0.91601306 sp|Q9D0F9|PGM1_MOUSE
106 -1.2426987 0.91601306 sp|Q91X52|DCXR_MOUSE
107 -1.2419586 0.49851555 sp|Q8R180|ERO1A_MOUSE
108 -1.238163 0.91601306 sp|P27046|MA2A1_MOUSE
109 -1.2355175 0.91601306 sp|P00405|COX2_MOUSE
110 -1.2326698 0.91601306 sp|Q922B1|MACD1_MOUSE
111 -1.2316475 0.49851555 sp|Q9D6F9|TBB4A_MOUSE
112 -1.2304764 0.91601306 sp|Q61081|CDC37_MOUSE
113 -1.2287579 0.91601306 sp|P58281-2|OPA1_MOUSE
114 -1.2281294 0.91601306 sp|Q3B7Z2|OSBP1_MOUSE
115 -1.2280521 0.91601306 sp|Q8R1F1|NIBL1_MOUSE
116 -1.2269764 0.91601306 sp|Q6Y7W8|GGYF2_MOUSE
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117 -1.2266569 0.91601306 sp|Q9Z0U1|ZO2_MOUSE
118 -1.2253742 0.91601306 sp|Q6PA06-2|ATLA2_MOUSE
119 -1.2230349 0.91601306 sp|Q3UMF0-2|COBL1_MOUSE
120 -1.2195797 0.91601306 sp|P49442|INPP_MOUSE
121 -1.219389 0.91601306 sp|Q9DCF9-2|SSRG_MOUSE
122 -1.2190657 0.49851555 sp|P61164|ACTZ_MOUSE
123 -1.2168465 0.91601306 sp|Q9DC16|ERGI1_MOUSE
124 -1.2116909 0.91601306 sp|O55028|BCKD_MOUSE
125 -1.2110748 0.49851555 sp|P53810|PIPNA_MOUSE
126 -1.2081051 0.91601306 sp|P53811|PIPNB_MOUSE
127 -1.2073975 0.91601306 sp|Q91WK2|EIF3H_MOUSE
128 -1.2065105 0.49851555 sp|Q80SW1|SAHH2_MOUSE
129 -1.2050934 0.91601306 sp|Q9WUL7|ARL3_MOUSE
130 -1.2028103 0.91601306 sp|Q8C181-2|MBNL2_MOUSE
131 -1.2007256 0.91601306 sp|Q9D1Q6|ERP44_MOUSE
132 -1.2003794 0.91601306 sp|P47857-2|PFKAM_MOUSE
133 -1.1973591 0.91601306 sp|Q8CIM3|D2HDH_MOUSE
134 -1.1967716 0.91601306 sp|P45878|FKBP2_MOUSE
135 -1.1963501 0.91601306 sp|Q8VCM8|NCLN_MOUSE
136 -1.1960773 0.91601306 sp|Q9DCS9|NDUBA_MOUSE
137 -1.1942635 0.91601306 sp|Q9D8C2|TSN13_MOUSE
138 -1.1915073 0.91601306 sp|Q05144|RAC2_MOUSE
139 -1.1868706 0.91601306 sp|Q6ZWQ7|SPCS3_MOUSE
140 -1.184555 0.91601306 sp|P62983|RS27A_MOUSE
141 -1.1835709 0.91601306 sp|Q64310|SURF4_MOUSE
142 -1.1805344 0.91601306 sp|Q9R112|SQOR_MOUSE
143 -1.1790028 0.91601306 sp|Q9DCT2|NDUS3_MOUSE
144 -1.1763353 0.49851555 sp|P70333|HNRH2_MOUSE
145 -1.1745644 0.91601306 sp|Q9CQZ5|NDUA6_MOUSE
146 -1.171978 0.91601306 sp|P99026|PSB4_MOUSE
147 -1.1718845 0.91601306 sp|Q9DBH5|LMAN2_MOUSE
148 -1.171689 0.49851555 sp|Q61133|GSTT2_MOUSE
149 -1.1700516 0.91601306 sp|P68510|1433F_MOUSE
150 -1.1697206 0.91601306 sp|Q9CZ44-3|NSF1C_MOUSE
151 -1.1675911 0.91601306 sp|Q9JM14|NT5C_MOUSE
152 -1.1669292 0.91601306 sp|P24547|IMDH2_MOUSE
153 -1.165226 0.91601306 sp|Q921X9|PDIA5_MOUSE
154 -1.16292 0.91601306 sp|Q80UM3|NAA15_MOUSE
155 -1.162157 0.91601306 sp|Q8JZU2|TXTP_MOUSE
156 -1.1541367 0.91601306 sp|Q9CYZ2|TPD54_MOUSE
157 -1.151825 0.91601306 sp|Q924M7|MPI_MOUSE
158 -1.1503906 0.49851555 sp|O35737|HNRH1_MOUSE
159 -1.1486397 0.91601306 sp|Q5YD48-2|A1CF_MOUSE
160 -1.1478958 0.91601306 sp|P60824|CIRBP_MOUSE
161 -1.1461182 0.49851555 sp|Q3UV17|K22O_MOUSE
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162 -1.1445503 0.91601306 sp|Q9D892|ITPA_MOUSE
163 -1.1439457 0.91601306 sp|Q3TJZ6|FA98A_MOUSE
164 -1.1354609 0.91601306 sp|Q9D0K2|SCOT1_MOUSE
165 -1.1338282 0.91601306 sp|P62141|PP1B_MOUSE
166 -1.1316261 0.91601306 sp|Q99J39-2|DCMC_MOUSE
167 -1.1280613 0.91601306 sp|P32233|DRG1_MOUSE
168 -1.1258507 0.91601306 sp|Q8R0X7|SGPL1_MOUSE
169 -1.1228218 0.91601306 sp|P62274|RS29_MOUSE
170 -1.1226807 0.91601306 sp|Q9JM76|ARPC3_MOUSE
171 -1.1201134 0.91601306 sp|Q9R1P0|PSA4_MOUSE
172 -1.1139317 0.91601306 sp|P47754|CAZA2_MOUSE
173 -1.1125727 0.91601306 sp|P28658|ATX10_MOUSE
174 -1.1081991 0.91601306 sp|Q01405|SC23A_MOUSE
175 -1.1076202 0.91601306 sp|P48193-2|41_MOUSE
176 -1.1073151 0.91601306 sp|Q9DC69|NDUA9_MOUSE
177 -1.1060591 0.49851555 sp|Q78ZA7|NP1L4_MOUSE
178 -1.0976181 0.91601306 sp|P61750|ARF4_MOUSE
179 -1.0975285 0.91601306 sp|Q9CQC9|SAR1B_MOUSE
180 -1.0948553 0.91601306 sp|Q9Z2X1-2|HNRPF_MOUSE
181 -1.0947847 0.91601306 sp|Q9JHW2|NIT2_MOUSE
182 -1.0917206 0.91601306 sp|Q9QYJ3|DNJB1_MOUSE
183 -1.0882874 0.91601306 sp|P51174|ACADL_MOUSE
184 -1.083662 0.91601306 sp|Q7TQI3|OTUB1_MOUSE
185 -1.0804901 0.91601306 sp|P70695|F16P2_MOUSE
186 -1.0790787 0.91601306 sp|Q6ZWU9|RS27_MOUSE
187 -1.0770531 0.91601306 sp|Q99LX0|PARK7_MOUSE
188 -1.076642 0.91601306 sp|Q8K1E0-2|STX5_MOUSE
189 -1.0762386 0.91601306 sp|Q99LC8|EI2BA_MOUSE
190 -1.0753365 0.91601306 sp|Q99KR3|LACB2_MOUSE
191 -1.072854 0.91601306 sp|Q9D1G1|RAB1B_MOUSE
192 -1.071846 0.91601306 sp|P61202-2|CSN2_MOUSE
193 -1.0705929 0.49851555 sp|Q9WV02-2|RBMX_MOUSE
194 -1.0703392 0.91601306 sp|P29391|FRIL1_MOUSE
195 -1.067997 0.49851555 sp|P55258|RAB8A_MOUSE
196 -1.0677948 0.91601306 sp|Q8K310|MATR3_MOUSE
197 -1.0526981 0.91601306 sp|Q9CR16|PPID_MOUSE
198 -1.047514 0.91601306 sp|Q91VF2|HNMT_MOUSE
199 -1.044919 0.91601306 sp|Q8VC30|TKFC_MOUSE
200 -1.0421238 0.91601306 sp|O88696|CLPP_MOUSE
201 -1.0341625 0.91601306 sp|P56380|AP4A_MOUSE
202 -1.0339527 0.91601306 sp|P61979-2|HNRPK_MOUSE
203 -1.0335789 0.91601306 sp|Q99LB6-2|MAT2B_MOUSE
204 -1.0331154 0.91601306 sp|Q9CPT4|MYDGF_MOUSE
205 -1.0248833 0.91601306 sp|Q9CQS8|SC61B_MOUSE
206 -1.0220718 0.49851555 sp|Q6IFZ6|K2C1B_MOUSE
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207 -1.0210285 0.91601306 sp|Q9DCT8|CRIP2_MOUSE
208 -1.0209751 0.91601306 sp|Q8VCR7|ABHEB_MOUSE
209 -1.0161228 0.91601306 sp|P63260|ACTG_MOUSE
210 -1.0129232 0.91601306 sp|Q6P8X1|SNX6_MOUSE
211 -1.0076065 0.91601306 sp|P61358|RL27_MOUSE
212 -0.9983959 0.91601306 sp|P27048|RSMB_MOUSE
213 -0.9941635 0.91601306 sp|P07758|A1AT1_MOUSE
214 -0.9922199 0.91601306 sp|Q9D7A6|SRP19_MOUSE
215 -0.98636055 0.91601306 sp|Q9QXT0|CNPY2_MOUSE
216 -0.98517704 0.91601306 sp|Q8BH64|EHD2_MOUSE
217 -0.98493385 0.91601306 sp|P97823-2|LYPA1_MOUSE
218 -0.98397064 0.49851555 sp|Q9CZ42-3|NNRD_MOUSE
219 -0.9828243 0.91601306 sp|Q64133|AOFA_MOUSE
220 -0.98198223 0.91601306 sp|Q6ZWR4-2|2ABB_MOUSE
221 -0.9791479 0.49851555 sp|Q9DCV7|K2C7_MOUSE
222 -0.9758949 0.49851555 sp|Q91VM5|RMXL1_MOUSE
223 -0.9753418 0.91601306 sp|Q9R1P3|PSB2_MOUSE
224 -0.96315384 0.91601306 sp|P34884|MIF_MOUSE
225 -0.9358063 0.49851555 sp|P17426-2|AP2A1_MOUSE
226 -0.9327469 0.91601306 sp|Q3UGR5|HDHD2_MOUSE
227 -0.93006516 0.91601306 sp|P60710|ACTB_MOUSE
228 -0.923213 0.49851555 sp|P17427|AP2A2_MOUSE
229 -0.8823776 0.91601306 sp|P23492|PNPH_MOUSE
230 -0.8738289 0.91601306 sp|P50543|S10AB_MOUSE
231 -0.872838 0.91601306 sp|P20108|PRDX3_MOUSE
232 -0.8728094 0.49851555 sp|Q922U2|K2C5_MOUSE
233 -0.8593445 0.91601306 sp|Q78XF5|OSTC_MOUSE
234 -0.83586407 0.49851555 sp|P61027|RAB10_MOUSE
235 -0.8286371 0.91601306 sp|P52480-2|KPYM_MOUSE
236 -0.7517929 0.91601306 sp|P00920|CAH2_MOUSE
237 -0.6766529 0.49851555 sp|Q8VED5|K2C79_MOUSE
238 -0.1389122 0.39426914 sp|P16015|CAH3_MOUSE
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